On this page
Quick Reference
Overview and Recommendations
Background
- •Define epilepsy as a clinical syndrome of recurrent unprovoked seizures, distinguishing between ictogenesis (the acute transition to a seizure) and epileptogenesis (the chronic process of brain transformation into a seizure-prone state). The condition affects approximately 1% of the population and carries significant risks of morbidity, cognitive decline, and sudden unexpected death in epilepsy (SUDEP).
- •Recognize the core pathophysiology involving the tripartite synapse, where disruptions in ion channels (e.g., SCN1A, KCNQ2) and glial regulation of glutamate (via TREK-1 channels) lead to neuronal hyperexcitability. In many cases, an initial insult such as traumatic brain injury or status epilepticus triggers neuroinflammation and maladaptive plasticity, cementing the epileptic network.
- •Classify seizures by onset as focal (originating in one hemisphere), generalized (involving bilateral networks from the start), or unknown. Focal seizures are further categorized by the preservation or impairment of awareness, which is a primary classifier in the 2025 ILAE update.
- •Identify key genetic variants that dictate clinical phenotypes, such as SCN1A loss-of-function in affecting inhibitory interneurons, or KCNQ2 variants leading to a spectrum from self-limited neonatal epilepsy to severe developmental and epileptic encephalopathy (DEE).
- •Understand the role of metabolic and inflammatory triggers, including succinic semialdehyde dehydrogenase deficiency (SSADHD) and autoimmune encephalitis, which may present with drug-resistant seizures and require targeted metabolic or immunosuppressive therapy.
Evaluation
- •Suspect epilepsy in any patient presenting with paroxysmal alterations in consciousness, motor activity, or sensory perception. Prioritize a meticulous reconstruction of the event from witnesses, as patient self-reporting is frequently inaccurate, especially in focal onset impaired awareness seizures (FIAS).
- •Ask about the pre-ictal phase to identify triggers such as sleep deprivation, fever, or specific reflex stimuli like reading. In cases of Febrile Infection-Related Epilepsy Syndrome (FIRES), look for a febrile illness occurring 24 hours to 7 days prior to the onset of status epilepticus.
- •Examine for systemic markers of genetic syndromes, such as macrocephaly in ODLURO syndrome (KMT2E variants) or distinct facial features and microcephaly in Mowat-Wilson syndrome. Assess for neurodevelopmental delays or regression, which suggest a DEE rather than a benign epilepsy syndrome.
- •Obtain a routine or sleep-deprived EEG within 24 hours of the first seizure event to maximize the diagnostic yield for interictal epileptiform discharges (IEDs). If the initial EEG is normal, utilize functional tests or sleep induction (e.g., using melatonin 5 mg in children) to increase sensitivity.
- •Order a high-resolution 3T MRI using a dedicated epilepsy protocol to rule out structural lesions such as focal cortical dysplasia (FCD), hippocampal sclerosis, or multinodular and vacuolating neuronal tumors (MVNT).
- •Rule out non-epileptic mimics by assessing serum biomarkers within 60 minutes of the event; a serum lactate > 2.5 mmol/L or elevated prolactin and ammonia levels strongly suggest an epileptic seizure over syncope or functional/psychogenic non-epileptic seizures (PNES).
- •Monitor for autonomic red flags, such as ictal heart rate increases > 50 bpm or significant peripheral oxygen desaturation (SpO2), which may serve as biomarkers for increased SUDEP risk.
- •Screen for pediatric-specific red flags, including bruising in non-exploratory areas (ears, neck, torso) in infants < 1 year old, which may indicate abusive head trauma as the underlying cause of new-onset seizures.
- •Consider genetic testing (e.g., epilepsy panels or whole-exome sequencing) in patients with early-onset seizures, developmental delay, or a family history of epilepsy, as over 1,000 genes are now associated with epileptic phenotypes.
- •Utilize the STAMP scale (Scale for Objective Diagnostic Components of Paroxysmal Events) to objectively grade the likelihood of an epileptic seizure versus syncope based on clinical semiology.
Management
- •Administer first-line monotherapy for focal epilepsy using Lamotrigine (titrated slowly to 100-200 mg BID) or Levetiracetam (500-1500 mg BID). Lamotrigine is preferred in patients of childbearing potential due to its lower teratogenic risk compared to other agents.
- •Avoid Valproate in women of childbearing potential whenever possible due to high risks of major congenital malformations and adverse neurodevelopmental outcomes; if required, use the lowest effective dose with concurrent folic acid supplementation.
- •Manage Infantile Epileptic Spasms Syndrome (IESS) urgently by initiating ACTH monotherapy, followed by a clinical and EEG assessment on Day 7; if spasms persist, add Vigabatrin (50 mg/kg/day, titrated up to 150 mg/kg/day) to the regimen.
- •Treat status epilepticus (seizure > 5 minutes) as a neurological emergency: start with IV Lorazepam 4 mg (repeated once if needed), followed immediately by a second-line ASM such as IV Levetiracetam 60 mg/kg (max 4500 mg) or Fosphenytoin 20 mg PE/kg.
- •Escalate to Cenobamate (starting at 12.5 mg/day and titrating slowly to 200-400 mg/day) for adults with drug-resistant focal seizures, as it has shown high potency in reducing seizure frequency across all focal subtypes.
- •Refer patients for a comprehensive presurgical evaluation if they fail two appropriately chosen and tolerated ASM trials (drug-resistant epilepsy). Surgical options include anterior temporal lobectomy (ATL) for mesial temporal lobe epilepsy or Laser Interstitial Thermal Therapy (LITT) for deep-seated lesions.
- •Consider palliative procedures such as Vagus Nerve Stimulation (VNS) or Responsive Neurostimulation (RNS) for patients who are not candidates for resective surgery or who have multifocal seizure onsets.
- •Monitor for medication-induced autonomic changes, such as hypohidrosis (reduced sweating) and hyperthermia in patients taking Zonisamide or Topiramate, particularly in warm environments.
- •Perform therapeutic drug monitoring (TDM) during pregnancy, as physiological changes (increased glomerular filtration) can significantly lower ASM plasma levels, necessitating dose adjustments to maintain seizure control.
- •Implement an Acute Seizure Action Plan for all patients, including rescue medications (e.g., intranasal Midazolam 5-10 mg) for clusters or prolonged events to prevent progression to status epilepticus.
- •Avoid routine ASM prophylaxis in seizure-naive patients with newly diagnosed brain tumors, as evidence from the SPRING trial suggests it does not meaningfully reduce the risk of a first seizure.
- •Evaluate for ASM withdrawal only after a minimum of 2 years of seizure freedom, counseling the patient that the risk of recurrence is approximately 15% compared to 7% if treatment is continued.
- •Refer for specialized metabolic management in cases of vitamin B6-dependent epilepsy (PLPBP-related), where high-dose pyridoxine is the definitive treatment.
- •Monitor cognitive and neuropsychiatric comorbidities, particularly ADHD (present in ~30% of pediatric cases) and depression, which can significantly impact quality of life and ASM adherence.
Board Review — High Yield
- •SCN1A mutation — The hallmark of Dravet Syndrome; avoid sodium channel blockers as they worsen seizures.
- •3 Hz spike-and-wave — Classic EEG finding for Childhood Absence Epilepsy.
- •Hypsarrhythmia — The chaotic EEG pattern associated with West Syndrome (Infantile Spasms).
- •Drug-Resistant Epilepsy — Defined as failure of 2 tolerated and appropriately chosen ASM schedules.
- •SUDEP — Sudden Unexpected Death in Epilepsy; risk is highest with uncontrolled generalized tonic-clonic seizures and nocturnal events.
- •Gelastic seizures — Associated with hypothalamic hamartomas; present as inappropriate bursts of laughter.
- •Todd's Paralysis — Focal neurological deficit (usually hemiparesis) following a focal seizure, typically resolving within 24 hours.
- •BECTS (SeLECTS) — Most common childhood epilepsy; characterized by centrotemporal spikes and nocturnal orofacial seizures.
Deep Dive — Evidence Details
Pathophysiology
- ▸Epilepsy pathophysiology converges on abnormal network excitability arising from genetic, synaptic, ion-channel, inflammatory, and glial mechanisms.[252][253]
- ▸A definitive molecular diagnosis was identified in 35.6% of 250 children with unexplained epilepsy undergoing exome sequencing.[303]
- ▸SCN1A loss of function impairs inhibitory interneuron signaling and accounts for more than 95% of Dravet syndrome cases.[1][250]
- ▸Potassium-channel dysfunction affects intrinsic excitability and fast-spiking interneuron function through KCNQ, KCNA2, KCNC1, and KCNJ4 mechanisms.[12][248][251][255]
- ▸GAT-1 loss of function, neuroinflammatory signaling, and astrocyte remodeling can amplify seizures while contributing to developmental impairment.[247][252][254]
- ▸Variant-specific functional effects and incomplete genotype–phenotype correlations mean that gene labels alone do not reliably predict epilepsy severity or phenotype.[242][256][304]
Overview
Epilepsy reflects recurrent, abnormal neuronal network activity produced by interacting genetic, cellular, synaptic, metabolic, inflammatory, and developmental mechanisms rather than a single disease process.[252]D[253]D Ion-channel dysfunction is a major pathogenic theme: variants affecting sodium, potassium, calcium, and GABA-transport systems can alter neuronal membrane excitability, action-potential generation, synaptic inhibition, or network synchrony.[242][245]C[247]D[248]D[251]D[255]D
The genetic contribution is substantial and clinically heterogeneous. In a tertiary-care pediatric cohort with unexplained epilepsy, exome sequencing identified a definitive pathogenic or likely pathogenic variant in 35.6% (89/250) of children, supporting molecular diagnosis as a major route to identifying disease mechanisms.[303]C The range of phenotypes caused by individual genes is broad: SCN1A variants are associated with self-limited genetic epilepsy with febrile seizures plus, Dravet syndrome, and neonatal or infantile developmental and epileptic encephalopathy (DEE).[244]C[304]C In a large MRI-negative cohort of early infantile DEE with burst-suppression EEG, 110 patients were identified from 1,540 individuals evaluated for suspected genetic epilepsies, underscoring the importance of genetic mechanisms even when structural MRI is unrevealing.[241]C
Excitatory–inhibitory imbalance
A central pathophysiological endpoint is impaired regulation of the balance between excitation and inhibition. SCN1A encodes NaV1.1, which is particularly important for inhibitory interneuron function; loss-of-function variants reduce GABAergic inhibitory signaling and produce neuronal hyperexcitability in GEFS+ and Dravet-spectrum disease.[1]D[250]D Dravet syndrome is caused by SCN1A loss of function in more than 95% of cases, and the resulting early-onset drug-resistant seizures coexist with developmental, motor, behavioral, and mortality-related complications.[1]D[249]D[305]D Experimental evidence further implicates astrocytes: Scn1a haploinsufficient mice show long-lasting hippocampal and cortical astrocyte remodeling from the period of disease aggravation at approximately postnatal days 20–35 through later stabilization.[254]D
SCN1A dysfunction is not mechanistically uniform. Functional studies of four variants affecting the same codon demonstrated divergent channel properties, consistent with variant-specific effects on phenotype.[304]C Loss-of-function mechanisms in SCN2A likewise do not reliably predict whether epilepsy will occur or which clinical phenotype will emerge, indicating that variant location, residual channel function, cellular expression, developmental timing, and modifying factors influence disease expression.[256]D SCN8A-associated epilepsy commonly involves de novo heterozygous variants, although inherited variants also occur; reported onset ranged from 10 minutes after birth to 2 years, illustrating the developmental breadth of sodium-channel epilepsies.[245]C
Potassium and calcium channel mechanisms
Potassium channels provide a major molecular restraint on neuronal firing. Kv7 channels encoded by KCNQ genes generate the neuronal M-current, described as an intrinsic “molecular brake” that limits pathological firing and represents a precision target in focal epilepsy.[248]D KCNA2 encodes Kv1.2, and KCNA2-related epilepsy is frequently associated with early onset, developmental impairment, and, in some patients, spike-and-wave activation during sleep; among 18 newly analyzed patients, the median seizure-onset age was 6 months and intellectual disability occurred in 83.3%.[251]D KCNC1 encodes Kv3.1, which is strongly expressed in parvalbumin-positive fast-spiking GABAergic interneurons; impaired excitability of these neurons provides a mechanism for defective high-frequency inhibition and developmental epileptic encephalopathy.[12]D
KCNJ4 encodes the inward-rectifier potassium channel Kir2.3. Rare variants identified in four unrelated individuals with refractory epilepsy and neurodevelopmental abnormalities disrupted channel function in electrophysiological assays, expanding the spectrum of potassium-channel epilepsies.[255]D CACNA1A encodes the Cav2.1 P/Q-type calcium channel, linking presynaptic calcium-dependent neurotransmission to a spectrum that includes epilepsy, ataxia, migraine, episodic ataxia, and spinocerebellar ataxia; a three-generation family carrying CACNA1A c.5610del demonstrated variable, including sex-stratified, penetrance.[242]
GABAergic, synaptic, and developmental mechanisms
SLC6A1 encodes GAT-1, the principal synaptic GABA transporter. Heterozygous loss-of-function variants cause a DEE characterized by early-onset epilepsy, intellectual disability, and autistic features, indicating that abnormal GABA handling can disrupt both seizure control and neurodevelopment.[247]D PRUNE1-related disease combines epilepsy with developmental delay and congenital brain malformations. In five patients homozygous for p.Asp106Asn, structural analyses focused on the DHH motif and its potential role in ion coordination, providing a proposed link between PRUNE1 dysfunction and ion-channel biology, although the mechanism remains investigational.[243]
Early developmental network dysfunction may produce distinctive electroclinical states. Early infantile DEE with burst-suppression is characterized by neonatal or early-infantile presentation, refractory seizures, and profound neurodevelopmental impairment; KCNQ2, STXBP1, and SCN2A are recognized causes, but the complete genetic spectrum remains broader.[241]C The severity of developmental outcome therefore reflects not only seizure burden but also the direct effects of gene dysfunction on neuronal maturation and network organization.[241]C[247]D[251]D
Neuroinflammation and glial remodeling
Neuroinflammation may promote epileptogenesis by converting injured or otherwise vulnerable neural tissue into a state capable of spontaneous recurrent seizures.[252]D Proposed mechanisms include activation of the NLRP3 inflammasome and P2X7 receptor, maturation of interleukin-1β, and engagement of MyD88 and PI3K/AKT/mTOR signaling. These pathways can increase NMDA-receptor activity and glutamate release while reducing GABAergic inhibition, thereby reinforcing hyperexcitability and structural plasticity.[252]D Astrocytic remodeling in Scn1a haploinsufficiency provides experimental evidence that non-neuronal cells may contribute to persistent network dysfunction rather than merely respond passively to seizures.[254]D
Therapeutic implications of mechanism
Mechanism-based therapies are increasingly aimed at correcting the causal molecular defect rather than only suppressing seizures. In mouse models, adenine base editing corrected the recurrent SCN1A-R613X variant and ameliorated Dravet phenotypes, while prime editing of the Scn1a-K1270T allele improved seizure phenotypes in a GEFS+ model.[249]D[250]D These findings remain preclinical and do not establish human efficacy.[249]D[250]D The imperfect correspondence between animal seizure-model potency and clinical antiseizure efficacy also cautions against assuming that suppression of experimentally induced seizures fully represents human disease biology.[253]D
History and Physical Examination
- ▸Characterize events chronologically and obtain eyewitness descriptions or video, with specific attention to impaired awareness, autonomic symptoms, postictal breathing, and recovery [34][322].
- ▸Review cardiovascular symptoms and risk factors; ECG and cardiac evaluation are adjunctive, because pediatric epilepsy studies describe subclinical conduction and repolarization abnormalities without establishing diagnostic ECG criteria [263][264].
- ▸Assess ASM adherence, adverse effects, weight, lipids, obesity risk, frailty, thyroid symptoms, and metabolic health [31][44][258][262][266].
- ▸In patients who may become pregnant, document pregnancy intention and ASM exposure because fetal-growth risk is being evaluated across monotherapy, polytherapy, and individual drug combinations [306].
- ▸Progressively worsening severe headache with seizures warrants careful examination for papilledema, focal deficits, and infection or structural disease, including neurocysticercosis where epidemiologically relevant [191].
- ▸Use MRI, EEG, ECG, and laboratory tests to answer questions raised by the history and examination; do not substitute imaging or physiologic biomarkers for clinical assessment [191][259][260][320][321].
Purpose and approach
The history and examination should establish whether episodic events are likely epileptic seizures, define seizure semiology and precipitants, identify comorbidities and treatment effects, and assess risks requiring urgent investigation. Recent evidence supports adding structured cardiovascular, respiratory, metabolic, endocrine, nutritional, functional, psychiatric, and reproductive assessments to the conventional neurologic examination, while recognizing that many reported biomarkers remain adjunctive rather than diagnostic [34][307][322].
Seizure history
Record age at onset, seizure frequency, duration, clustering, diurnal pattern, precipitating factors, injuries, recovery time, medication adherence, and the presence of prolonged or recurrent seizures without recovery. Characterize the event chronologically: aura or focal symptoms; behavioral arrest; impaired awareness; automatisms; tonic, clonic, atonic, or myoclonic movements; eye or head deviation; language disturbance; autonomic symptoms; cyanosis; incontinence; and postictal confusion, headache, focal weakness, or sleep. Obtain an eyewitness account and, when available, smartphone video. Document whether symptoms suggest autonomic involvement, because a prospective phase 3 validation study evaluated wearable ECG seizure detection specifically in patients with autonomic ictal heart-rate changes and automated assessment of impaired consciousness [34].
Ask specifically about palpitations, presyncope, syncope, chest discomfort, dyspnea, abnormal breathing, and postictal unresponsiveness. Epilepsy cohorts have demonstrated altered 24-hour heart-rate-variability measures, with investigation of SDNN, RMSSD, pNN50, low- and high-frequency power, and the LF/HF ratio, and assessment of whether these abnormalities vary with disease duration, hippocampal atrophy, or seizure type [307]. In temporal lobe epilepsy, interictal autonomic and respiratory chemoregulatory dysfunction has been studied in relation to central autonomic-network disruption and SUDEP risk [322]. Accordingly, ask about nocturnal seizures, unwitnessed events, postictal breathing abnormalities, and family observations of prolonged recovery; these findings should prompt individualized SUDEP-risk assessment rather than serve as stand-alone diagnostic criteria [322].
Cardiac history should include structural heart disease, arrhythmia, unexplained fainting, family history of sudden death, and use of QT-prolonging or other cardiac-active drugs. Pediatric epilepsy studies have examined QT-corrected dispersion, Tpeak–Tend intervals and ratios, P-wave dispersion, and other conduction or repolarization indices, including differences between emergency and interictal outpatient recordings [264]. Interictal T-wave alternans, a marker of repolarization instability, has also been evaluated in children with drug-resistant epilepsy before and after successful epilepsy surgery [263]. These findings support targeted cardiovascular review and ECG when clinically indicated, not diagnosis of epilepsy by ECG alone [263][264].
Medication, endocrine, metabolic, and reproductive history
For every antiseizure medication (ASM), record dose, timing, duration, adherence, recent changes, adverse effects, and exposure to polytherapy. Ask about weight change, appetite, fatigue, sedation, cognitive slowing, mood symptoms, tremor, gait disturbance, rash, and menstrual or sexual effects. A systematic review and meta-analysis found that ASM-associated lipid and weight effects differ by drug, treatment duration, and patient subgroup; therefore, weight and cardiometabolic history should be reviewed longitudinally [31]. Population-based data have also examined obesity in epilepsy in relation to genetic susceptibility, lifestyle factors, and commonly used lamotrigine, valproate, carbamazepine, and levetiracetam [262].
Assess diet, physical activity, alcohol and recreational-drug use, sleep, and socioeconomic barriers to treatment. Document unintentional weight loss, exhaustion, slow gait, reduced activity, and weak grip: these are the five components of the modified Fried frailty phenotype used in a large prospective cohort examining frailty and incident epilepsy [258]. Frailty status may influence history reliability, injury risk, treatment tolerance, and the need for falls and functional assessment [258].
Ask about thyroid disease, goiter, heat or cold intolerance, constipation or diarrhea, palpitations, growth concerns, and developmental or pubertal changes. Pediatric epilepsy studies have evaluated TSH, free T4, free T3, thyroid antibodies, thyroid volume, central thyroid-hormone sensitivity indices, peripheral hormone metabolism, glucose, insulin, and lipid measures in relation to ASM exposure and metabolic health [44]D[266]. These findings support symptom-directed thyroid and metabolic assessment rather than assuming that normal routine tests exclude all treatment-associated endocrine effects [44]D[266].
For patients who could become pregnant, document pregnancy intention, contraception, folate use, prior pregnancy outcomes, and current ASM exposure. Prospective EURAP registry data specifically evaluate poor fetal growth after prenatal ASM monotherapy, polytherapy, and exposure to individual drugs or combinations; pregnancy planning and fetal-growth surveillance should therefore be incorporated into the history [306].
Neurologic and general examination
Perform a complete neurologic examination, including mental status, language, cranial nerves, visual fields, motor strength, tone, reflexes, sensation, coordination, gait, tandem gait, and signs of lateralization. Examine for focal deficits, neurocutaneous markers, meningism, cognitive impairment, medication-related movement abnormalities, and injuries from falls or convulsions. In patients with severe or progressively worsening headache, document headache tempo, vomiting, visual symptoms, papilledema, focal deficits, altered cognition, and systemic features. A Burkina Faso study specifically investigated cerebral CT findings and neurocysticercosis among people with epileptic seizures and progressively worsening severe headaches, underscoring the importance of this symptom combination in relevant epidemiologic settings [191]D.
Record height, weight, body-mass trend, waist circumference when appropriate, blood pressure, pulse, orthostatic measurements, temperature, oxygen saturation, respiratory pattern, and evidence of trauma. Physical examination should include cardiovascular auscultation, peripheral pulses, respiratory examination, thyroid palpation, skin examination, and assessment for frailty and nutritional compromise [31][44]D[258][264].
Examination-linked investigations
History and examination guide selection of EEG, ECG, neuroimaging, laboratory testing, and specialist referral. Ictal EEG and heart rate have been studied as potential treatment or outcome criteria in ECT, but their prognostic value remains controversial; these markers should not be presented as validated epilepsy diagnostic thresholds [320]. MRI may reveal hippocampal volume loss in mesial temporal lobe epilepsy, subtle abnormalities in otherwise non-lesional epilepsy at 7 T, thalamic asymmetry, or brainstem-substructure differences in generalized epilepsy, but these are imaging findings and should complement—not replace—the clinical history and examination [259]C[260][261]C[321].
| Domain | Key elements | Evidence |
|---|---|---|
| Seizure semiology | Onset, awareness, motor features, autonomic symptoms, duration, clustering, postictal state | [34][322] |
| Cardiovascular/autonomic | Syncope, palpitations, family history, nocturnal events, breathing abnormalities, pulse, orthostatics, ECG when indicated | [263][264][307][322] |
| Medication/metabolic | ASM exposure, adherence, weight, appetite, lipids, activity, frailty, endocrine symptoms | [31][44]D[258][262][266] |
| Reproductive | Pregnancy intention, contraception, folate, prior outcomes, ASM regimen | [306] |
| Neurologic/general | Mental status, focal signs, gait, injuries, papilledema, headache features, skin and thyroid examination | [191]D[258] |
Clinical Features and Seizure Variants
- ▸Brain-responsive neurostimulation (RNS) achieves a 67% median reduction in focal seizures at 3 years.
- ▸Super-refractory status epilepticus (SRSE) is defined by persistence >24 hours despite anesthetics.
- ▸Vagus Nerve Stimulation (VNS) is an emerging adjunctive treatment for SRSE and NORSE.
- ▸Genetic variants in UNC13A, YWHAG, and CACNA1A define specific pediatric epilepsy phenotypes.
- ▸Rural patients in the US face higher mortality and higher rates of status epilepticus presentation.
- ▸Epileptiform EEG patterns post-cardiac arrest predict poor neurological recovery.
Focal Seizure Variants and Diagnostic Challenges
Focal seizures remain a primary clinical presentation in drug-resistant epilepsy, often requiring advanced neuromodulation when medication fails. In a large post-approval study of brain-responsive neurostimulation (RNS System), patients with focal epilepsy demonstrated a median percent change in seizure frequency of 67% at 3 years [268]. Clinical recognition of focal seizures can be challenging; for instance, in patients with pleomorphic xanthoastrocytomas (PXAs), 31.6% had unrecognized focal seizures prior to their index presentation [276]. Furthermore, non-invasive detection of focal seizures is evolving through multimodal wearable devices (e.g., Sensor Dot) using EEG and ECG, which aim to provide accurate out-of-hospital monitoring for diverse focal seizure types [281].
Status Epilepticus and Super-Refractory Variants
Super-refractory status epilepticus (SRSE) is defined as status epilepticus persisting for more than 24 hours despite anesthetic management [271]C. This condition carries high morbidity and requires aggressive intervention. Surgical options, including resective surgery, multiple subpial transections, and Vagus Nerve Stimulation (VNS), are increasingly utilized [271]C. VNS has specifically shown promise as an adjunctive therapy for SRSE, including New-Onset Refractory Status Epilepticus (NORSE), with some patients achieving seizure cessation during hospitalization [70].
In the management of SRSE, intravenous ketamine is employed, with treatment response potentially predicted by specific inflammatory biomarkers and EEG patterns [272]C. Notably, peri-ictal abnormalities on diffusion-weighted MRI (DWI-PMA) are well-documented in status epilepticus; however, patients with idiopathic generalized epilepsy (IGE) who develop SE show lower rates of these abnormalities compared to those with other etiologies, correlating with generally more favorable outcomes [275].
Pediatric and Genetic Epilepsy Phenotypes
Genetic etiologies are major contributors to pediatric epilepsy, particularly those complicated by status epilepticus [86]D. Several specific genetic syndromes have recently been characterized:
- YWHAG-NDD: Associated with early-onset epilepsy and epileptic encephalopathy; natural history studies are ongoing to define its progression [273].
- PTEN Hamartoma Tumor Syndrome (PHTS): While primarily known for tumor risks, PHTS is associated with a significant prevalence of epilepsy, necessitating clinical management guidelines [280].
- UNC13A-related Disorders: These present with diverse epilepsy phenotypes in children, with missense variants often localized in the Munc13-1 hinge regions [283]C.
- CACNA1A Variants: Mutations such as c.5610del can result in a spectrum of epilepsy, ataxia, and migraine, with evidence suggesting sex-stratified penetrance [242].
- Infantile Epileptic Spasms Syndrome (IESS): This age-specific encephalopathy is linked to neuroinflammation, specifically the HMGB1-TLR4 signaling pathway, which may serve as a clinical biomarker for treatment response [278].
Prognostic Indicators and Clinical Outcomes
Predicting outcomes in epilepsy involves both clinical and environmental factors. In survivors of cardiac arrest, the presence of epileptiform patterns on EEG and clinical myoclonic seizures are strong predictors of unfavorable neurological outcomes [270]. For patients undergoing VNS, prognostic factors for a positive response include age at onset, age at implantation, and genetic etiology [269].
Environmental and systemic factors also play a role; in the United States, rural residence is associated with higher in-hospital mortality and a higher likelihood of presenting in status epilepticus compared to urban counterparts, likely due to limited access to specialized epilepsy centers [277]. Additionally, seizure-type-specific disruptions in autonomic regulation, such as impaired hypercapnic cardioventilatory responses, are observed in chronic generalized tonic-clonic models, potentially increasing the risk of Sudden Unexpected Death in Epilepsy (SUDEP) [265].
| Gene/Condition | Clinical Features | Evidence Level |
|---|---|---|
| UNC13A | Pediatric neurodevelopmental disorder; missense variants in Munc13-1 | 4 [283]C |
| YWHAG | Early-onset epilepsy; 14-3-3 protein family involvement | 2b [273] |
| CACNA1A | Epilepsy, ataxia, and migraine; sex-stratified penetrance | 3b [242] |
| IESS | Infantile spasms; HMGB1-TLR4 neuroinflammatory markers | 3b [278] |
| PXA | Tumor-related epilepsy; 31.6% unrecognized focal seizures | 3b [276] |
Diagnosis and Workup
- ▸EEG should be performed within 24 hours of a first seizure to reduce the risk of status epilepticus and ICU admission [88].
- ▸Genetic testing is indicated in early-onset or syndromic epilepsies, as over 1,000 genes are now linked to the condition [90].
- ▸Advanced neuroimaging, including fMRI and AI-assisted EZ localization, is critical for presurgical planning in drug-resistant cases [92, 106].
The diagnosis of epilepsy is a multi-dimensional process that integrates clinical semiology, electrophysiological data, and advanced neuroimaging to identify the underlying etiology and localize the epileptogenic zone (EZ) [89]. Early and accurate diagnosis is critical, as delays in performing an electroencephalogram (EEG) after a seizure event significantly increase the risk of progression to status epilepticus (SE) and subsequent intensive care unit (ICU) admission [88]D.
Diagnostic Criteria
Epilepsy is formally diagnosed based on the occurrence of at least two unprovoked seizures occurring >24 hours apart, or one unprovoked seizure with a high probability of recurrence (at least 60%) over the next 10 years. In pediatric populations, the workup of first seizure-like events requires careful differentiation from non-epileptic mimics, with future epilepsy risk being higher in children with abnormal baseline EEGs or specific neuroimaging findings [91]. For specialized forms such as diffuse glioma-related epilepsy (dGRE), diagnosis requires spatial correlation between the tumor and the EZ, often necessitating a combination of EEG and molecular biomarkers [89].
Laboratory and Genetic Testing
Laboratory workup aims to identify metabolic, genetic, or inflammatory triggers.
- Genetic Testing: Genetic epilepsies involve pathogenic variants in over 1,000 genes [90]. Early genotype-phenotype interpretation is essential for precision . For example, PLPBP-related vitamin B6-dependent epilepsy presents with severe neurodevelopmental delay and requires specific genetic confirmation [93].
- Metabolic Markers: In cases of infantile epileptic spasms syndrome (IESS), a 7-day assessment of response to adrenocorticotropic hormone (ACTH) is used to guide sequential treatment with vigabatrin (VGB) [98].
- Inflammatory Biomarkers: In insular gliomas, peripheral inflammatory cell counts may serve as biomarkers for brain reorganization and associated epilepsy [105]D.
Electrodiagnostic Studies
EEG remains the gold standard for confirming network hyperexcitability. Guidelines emphasize the use of "functional tests" (formerly stress tests) to increase diagnostic yield [94][95].
- Routine and Sleep-Deprived EEG: Standard scalp EEG (scEEG) may miss interictal epileptiform discharges (IEDs), particularly those originating in the mesial temporal lobe (MTL). Advanced Support Vector Machine classifiers can now detect "hidden" MTL IEDs on scEEG with high accuracy using 58 specific features [111]D.
- Sleep Monitoring: Sleep-predominant network hyperexcitability is a key finding in early-stage Alzheimer's disease, where IEDs may accelerate cognitive decline [96].
- Long-term Monitoring: Video-EEG monitoring is essential for characterizing seizure semiology. In idiopathic generalized epilepsy (IGE), absence status epilepticus (ASE) is a frequent but often misdiagnosed presentation [62]C.
- Automated Detection: Deep learning models, such as the Multi-scale Kernel and Electrode Attention Network (MKEANet), allow for automated seizure detection from full-channel EEG signals without information loss [102]D[113]D.
Neuroimaging
High-resolution MRI using an epilepsy protocol is the first-line imaging modality to detect structural lesions such as focal cortical dysplasia or tumors [89][106]D.
- Advanced MRI Techniques: Morphometric analysis in conditions like self-limiting epilepsy with centrotemporal spikes (SeLECTS) reveals cortical thinning and subcortical volume changes linked to cognitive function [103]D. Functional MRI (fMRI) is used to assess the default mode network (DMN) and somatomotor network (SMN), which are frequently altered in focal epilepsy [104]D.
- SUDEP Risk Assessment: Breath-holding fMRI can identify brainstem respiratory center dysfunction in patients at risk for sudden unexpected death in epilepsy (SUDEP) [110]D.
- Artificial Intelligence (AI): AI architectures are increasingly used for EZ localization, segmentation of resection cavities, and predicting surgical outcomes [92][106]D.
Diagnostic Algorithm
- Step 1: Clinical Assessment: Detailed history of the event, semiology, and family history [90][91].
- Step 2: Initial EEG: Perform within 24 hours of the event to minimize SE risk [88]D. Use functional tests if the initial routine EEG is normal [95].
- Step 3: Structural Imaging: High-resolution MRI (3T preferred) with epilepsy-specific sequences [89].
- Step 4: Specialized Workup: If drug-resistant, proceed to long-term video-EEG, genetic panels [90], or metabolic screening [93].
- Step 5: Presurgical Evaluation: For surgical candidates, utilize stereo-electroencephalography (sEEG), which is less invasive than subdural electrodes [101]D, and integrate intraoperative ultrasound (ioUS) with depth-electrode electrocorticography (iECoG) for real-time EZ delineation [108]D.
| Test | Primary Finding | Timing | Clinical Utility |
|---|---|---|---|
| Scalp EEG | Interictal epileptiform discharges (IEDs) | Within 24h of seizure | Confirms diagnosis; predicts recurrence [88]D[91] |
| High-Res MRI | Structural lesions (e.g., FCD, glioma) | At initial workup | Identifies etiology; guides surgery [89][106]D |
| Genetic Panel | Pathogenic variants (e.g., KCNQ2, PLPBP) | Early in pediatric cases | Precision diagnosis; guides therapy [90][93] |
| sEEG | Intracranial seizure onset zone | Presurgical phase | Less invasive than subdural grids [101]D |
| fMRI | Network connectivity/Respiratory center | Presurgical/SUDEP screening | Evaluates functional risk [104]D[110]D |
Differential Diagnosis of Epilepsy
- ▸Serum lactate and ammonia measured within 60 minutes are highly effective for distinguishing epileptic seizures from syncope and functional seizures.
- ▸Home video recordings provide high interobserver reliability and diagnostic accuracy for differentiating sleep-related hypermotor epilepsy from non-epileptic disorders of arousal.
- ▸Advanced imaging like MR fingerprinting and metabolic network analysis can identify subtle epileptogenic lesions that conventional MRI may miss.
The differential diagnosis of epilepsy is broad, as many transient neurological events can mimic epileptic seizures (ES). Accurate differentiation is critical because misdiagnosis leads to inappropriate treatment with antiseizure medications (ASMs) and delays the of the underlying condition [119]D[126]D. The diagnostic process relies on a combination of clinical semiology, serum biomarkers, and electrophysiological data to distinguish ES from functional seizures, syncope, and sleep disorders [121][139]D.
Diagnostic Criteria
Formal diagnosis of epilepsy requires evidence of an enduring predisposition to generate seizures [119]D. The following criteria are utilized to differentiate epilepsy from its mimics:
- Required Features: At least one unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years [119]D.
- Supportive Features: Presence of interictal epileptiform discharges (IEDs) on EEG, though these can occasionally be incidental in healthy infants [133]D; focal lesions on MRI such as multinodular and vacuolating neuronal tumors (MVNT) [117]C or focal cortical dysplasia (FCD) [129]D; and specific serum biomarker elevations (e.g., lactate, prolactin) within 60 minutes of the event [121][142]D.
- Exclusion Criteria: Events clearly triggered by transient systemic factors (e.g., hypoglycemia, acute alcohol withdrawal, or hyponatremia) are classified as acute symptomatic seizures rather than epilepsy [126]D. Events with purely psychological triggers and no EEG correlate are classified as functional/psychogenic non-epileptic seizures (PNES) [122][135]D.
Laboratory Tests
Laboratory evaluation is most effective when performed immediately following a paroxysmal event. Serum biomarkers help distinguish ES from functional/cognitive seizures (FCS) and syncope [121].
- Lactate and Ammonia: Serum lactate and ammonia levels are significantly higher in patients with ES compared to those with FCS or syncope when measured within 1 hour of the event [121]. Lactate is particularly sensitive for generalized tonic-clonic seizures due to intense muscle contraction and anaerobic metabolism.
- Prolactin and Cortisol: A significant rise in serum prolactin and cortisol is observed within 20–60 minutes after an ES, whereas these levels typically remain stable or show minimal change after PNES [142]D.
- Neurofilament Light (NfL) and GFAP: Plasma NfL and glial fibrillary acidic protein (GFAP) are elevated in patients with chronic epilepsy compared to those with PNES, reflecting cumulative neuroaxonal and astrocytic injury [125]D[140]D.
- Metabolomic Profiling: NMR-based metabolomics can differentiate (AE) from drug-resistant epilepsy (DRE) by identifying distinct plasma signatures [141]D.
Imaging
Neuroimaging is essential to identify structural mimics or triggers of seizures.
- Magnetic Resonance Imaging (MRI): The modality of choice. It can identify rare tumors like MVNT, which present as T2/FLAIR hyperintense subcortical nodules that may mimic other dysplastic lesions [117]C.
- MR Fingerprinting (MRF): This advanced technique uses T1 and T2 relaxometry maps to differentiate epileptogenic cortical malformations from non-epileptogenic ones with higher precision than conventional MRI [129]D.
- PET and Network Analysis: 18F-FDG-PET metabolic networks can help differentiate "temporal plus" epilepsy (involving the insula) from isolated temporal lobe epilepsy (TLE) [132]D.
Electrodiagnostic Studies
EEG remains the gold standard for supporting a diagnosis of epilepsy, though its sensitivity is limited in the interictal period.
- Sleep-Deprived EEG: While sleep deprivation is commonly used to increase the yield of IEDs, meta-analyses show conflicting evidence regarding its overall diagnostic superiority over standard EEG [115]. In pediatric populations, 5 mg of melatonin is an effective and better-tolerated alternative to sleep deprivation for inducing sleep during nap-EEGs [116].
- Video-EEG Monitoring (VEM): Long-term VEM is the definitive tool for capturing semiology and simultaneous electrographic correlates. It is crucial for distinguishing sleep-related hypermotor epilepsy (SHE) from disorders of arousal (DoA) [130]D.
- Cortical Myoclonus Studies: In conditions like Familial Adult Myoclonus Epilepsy (FAME), electrophysiological studies must demonstrate cortical hyperexcitability to differentiate the tremor-like myoclonus from (ET) [118]D.
Diagnostic Algorithm
The following protocol should be used when a patient presents with a transient loss of consciousness or paroxysmal motor event:
- Step 1: Clinical History and Semiology: Obtain a detailed description from witnesses. Use the STAMP scale (Scale for Objective Diagnostic Components of Paroxysmal Events) to grade the likelihood of ES vs. syncope [139]D. Review home videos if available, as they have high diagnostic accuracy for functional seizures [122][130]D.
- Step 2: Immediate Post-Event Bloods: Within 60 minutes, draw serum lactate, ammonia, and prolactin. Elevated lactate (>2.5 mmol/L) strongly suggests ES over syncope or PNES [121].
- Step 3: Baseline EEG and MRI: Perform a standard EEG to look for IEDs. Order a high-resolution MRI (3T preferred) with an epilepsy protocol to rule out structural lesions like FCD or MVNT [117]C[129]D.
- Step 4: Specialized Testing: If the diagnosis remains uncertain, proceed to sleep-deprived EEG or VEM. For suspected autoimmune cases, check for neural antibodies and consider plasma metabolomics [141]D. For suspected FAME, perform electrophysiological testing for cortical myoclonus [118]D.
- Step 5: Cardiorespiratory Monitoring: In focal epilepsy, monitor for ictal central apnea (ICA), which may be a marker for specific genetic etiologies like DEPDC5 mutations and carries a risk for SUDEP [128]D[131]D.
| Test | Finding in Epilepsy | Timing | Sensitivity | Specificity |
|---|---|---|---|---|
| Serum Lactate | Elevated (>2.5 mmol/L) | <60 min post-event | High (for GTCS) | High |
| Serum Prolactin | Significant rise | 20–60 min post-event | Moderate | High |
| Interictal EEG | IEDs (spikes/waves) | Any time | Low (25-50%) | High |
| Video-EEG | Ictal electrographic discharge | During event | Gold Standard | Very High |
| MRI (3T) | FCD, MVNT, or Sclerosis | Any time | Moderate | High |
| Home Video | Stereotyped semiology | During event | Moderate | High [122][130]D |
Surgical and Interventional Management
- ▸Resective surgery is the most effective treatment for drug-resistant focal epilepsy, with complete EZ resection being the primary predictor of success [108, 144].
- ▸SEEG is the preferred invasive monitoring modality for deep-seated or complex networks due to its lower morbidity compared to subdural grids [101, 146].
- ▸Neuromodulation (VNS, RNS, DBS) serves as a critical palliative option for patients who are not candidates for resective surgery [74, 156, 164].
Surgical intervention is the definitive treatment for the approximately 33% of epilepsy patients who remain drug-resistant despite optimized medical therapy [144]. While resective surgery remains the gold standard for achieving seizure freedom, the field is rapidly evolving toward personalized, network-based interventions and minimally invasive techniques [165]D. Early surgical referral is critical, particularly in pediatric populations with focal cortical dysplasia (FCD), where intervention prior to meeting formal drug-resistance criteria may improve long-term neurodevelopmental and seizure outcomes [160]D.
Step 1: Presurgical Evaluation and Localization
The primary goal of the presurgical workup is to delineate the epileptogenic zone (EZ) while preserving eloquent cortex. This often requires a transition from non-invasive monitoring to invasive intracranial electroencephalography (iEEG).
- Multimodal Mapping: Utilize 3T MRI, PET, and ictal SPECT to identify structural and functional abnormalities. In cases of polymicrogyria (PMG), surgical success depends heavily on identifying the specific localized network, as PMG-related epilepsy often involves complex cortical malformations [147].
- Stereoelectroencephalography (SEEG): SEEG is preferred over subdural grids for its ability to sample deep-seated structures (e.g., the cingulate gyrus or insula) with lower morbidity [101]D[146]. For planning, dedicated MR arteriography-venography (MRAV) is superior to standard contrast-enhanced T1-weighted MRI for visualizing vascular structures and planning avascular trajectories to minimize hemorrhage risk [161]D.
- Electrode Implantation: Robot-assisted SEEG implantation offers comparable accuracy and safety to traditional frame-based methods while potentially increasing procedural efficiency [150].
Step 2: Resective and Disconnective Procedures
Resective surgery aims for the complete removal of the EZ, which is the strongest predictor of postoperative seizure freedom [108]D.
- Anterior Temporal Lobectomy (ATL): The most common procedure for mesial temporal lobe epilepsy (MTLE). In patients over 50 years of age or those with significant comorbidities, temporal lobe disconnection may be a safer alternative to formal resection, reducing the risk of vascular complications [155]C.
- Lesionectomy: Targeted resection of highly epileptogenic lesions such as gangliogliomas. Postoperative seizure freedom is high, and anti-seizure medication (ASM) withdrawal can often be considered within 2 years if the patient remains seizure-free [154].
- Hemispherectomy: In infants with catastrophic hemispheric epilepsy, modified functional hemispherectomy (combining hemispherotomy and anatomical resection) is effective and physiologically tolerated, despite the young age [162]D.
- Corpus Callosotomy: A palliative procedure for drop attacks. Total corpus callosotomy (TCC) provides superior seizure reduction compared to anterior (ACC) or posterior (PCC) callosotomy, though it carries a higher risk of disconnection syndrome [153].
Step 3: Minimally Invasive Interventions
Laser Interstitial Thermal Therapy (LITT) has emerged as a significant alternative for patients seeking less invasive options or those with deep-seated lesions.
- LITT Protocol: Under real-time MRI thermometry, a laser fiber is used to ablate the EZ. In nontumoral epilepsy, LITT offers shorter hospital stays and faster recovery than open surgery, though open resection may still provide slightly higher rates of complete seizure freedom [144].
- Special Populations: In children with (TSC), LITT can target specific tubers, leading to significant reductions in seizure frequency and potentially allowing for a reduction in ASM burden [166]D. For tumor-associated epilepsy, LITT can be combined with a stereotactic biopsy in a single session to provide histomolecular diagnosis before ablation [168]D.
Step 4: Neuromodulation for Non-Resectable Epilepsy
When the EZ involves eloquent cortex or is multifocal, neuromodulation is the preferred strategy.
- Vagus Nerve Stimulation (VNS): A palliative option that reduces seizure frequency and may decrease the incidence of status epilepticus in pediatric populations [74].
- Responsive Neurostimulation (RNS): A closed-loop system that detects and stimulates in response to specific electrographic patterns. Targeting the pulvinar nucleus with RNS is an emerging strategy for refractory posterior quadrant epilepsy [156]C.
- Deep Brain Stimulation (DBS): Typically targets the anterior nucleus of the thalamus (ANT). For multifocal drug-resistant epilepsy, 4-lead DBS systems are being utilized to cover broader seizure networks [164]D.
Step 5: Intraoperative Guidance and Monitoring
To optimize the extent of resection, surgeons utilize real-time feedback mechanisms.
- Intraoperative Ultrasound (ioUS): Provides real-time anatomical feedback to account for brain shift after craniotomy [108]D.
- Intraoperative Electrocorticography (iECoG): Used to delineate the EZ acutely. High-density (HD) grids are more effective at detecting sporadic interictal activity than standard strip electrodes [167]D. The absence of epileptiform activity on post-resection iECoG is associated with improved seizure outcomes in pediatric patients [159]D.
- Functional Mapping: In the language-dominant hemisphere, asleep-awake-asleep (AAA) anesthesia allows for intraoperative language mapping, which is essential to minimize postoperative language decline [158]D.
Step 6: Postoperative and Transition
Postoperative care focuses on monitoring for complications and assessing cognitive changes.
- Cognitive Assessment: Patients must be monitored for declines in language (specifically confrontation naming) and executive function [149][152]. Language outcomes should be formally assessed within the first 2 years post-surgery [149].
- ASM Titration: ASM withdrawal should be gradual. In patients with post-stroke epilepsy or vascular insults, the decision to taper medications depends on achieving at least 12-24 months of seizure freedom [148].
| Intervention | Primary Indication | Typical Outcome | Key Risk/Complication | Evidence Level |
|---|---|---|---|---|
| Open Resection | Focal DRE, MRI-positive | High seizure freedom | Language/Memory decline | 2a [144][152] |
| LITT | Deep lesions (e.g., HH), TSC | Minimally invasive | Visual field deficits | 2a [144][166]D |
| SEEG | EZ Localization | Diagnostic accuracy | Intracranial hemorrhage | 2a [146][157]C |
| VNS | Multifocal DRE, Palliative | Seizure frequency reduction | Hoarseness, cough | 2b [74] |
| DBS (ANT) | Multifocal/Generalized DRE | Seizure frequency reduction | Depression, paresthesia | 5 [164]D |
| Callosotomy | Drop attacks, Atonic seizures | Reduction in falls | Disconnection syndrome | 2a [153] |
Special Populations: Pediatrics, Pregnancy, and Geriatrics
- ▸Levetiracetam is effective and cardiac-safe for pediatric epilepsy monotherapy [284, 288].
- ▸Perampanel shows a 47.4% responder rate at 12 months in children as young as 7 months [290].
- ▸In utero exposure to lamotrigine and levetiracetam does not appear to impair long-term neurocognition [289].
- ▸Severe maternal morbidity is a risk factor for epilepsy in offspring [294].
- ▸Late-onset epilepsy (LOE) in seniors is frequently comorbid with TBI, stroke, and hydrocephalus [293, 299].
- ▸Sedatives like propofol and midazolam can mask epileptiform activity on EEG [287].
Pediatrics
Pediatric epilepsy management requires addressing unique etiologies, such as tubulinopathies, which present with significant genotypic and phenotypic heterogeneity. Variants in genes like TUBA1A, TUBB2A, and TUBB3 are associated with diverse neurodevelopmental disorders and seizure profiles [292]C. Recent evidence highlights the efficacy of Levetiracetam (LEV) as a primary treatment; a 2026 meta-analysis confirms its favorable pharmacokinetics and efficacy in achieving seizure freedom and ≥50% responder rates in children up to 16 years of age [284]. Furthermore, longitudinal data indicates that one year of LEV monotherapy in children with genetic generalized epilepsy does not significantly alter cardiac repolarization or echocardiographic parameters [288]C.
For drug-resistant epilepsy (DRE) in young children, adjunctive therapies show promise. Perampanel (PER) administered to children aged 7–46 months resulted in a 39.5% responder rate at 3 months, increasing to 47.4% by 12 months [290]. Cenobamate has also emerged as a viable adjunctive option for pediatric focal DRE, though data remains more limited than in adults [301]. In developmental and epileptic encephalopathies (DEEs) such as Dravet and Lennox-Gastaut syndromes, pharmaceutical-grade cannabidiol (CBD) is effective, though its impact varies by age band and clobazam co-medication [285].
Beyond pharmacology, the psychosocial burden is significant. Stigma negatively impacts the social, emotional, and physical wellbeing of children [291]. Families often engage in intensive 'information work' to manage the intersection of sleep disturbances and seizures, highlighting the need for behavioral sleep interventions [286]. Additionally, children with intellectual disabilities face a higher risk of incident challenging behaviors following the onset of new physical health or sensory impairments [296].
Pregnancy and Maternal Factors
Management during pregnancy necessitates balancing seizure control with fetal neurodevelopment. A 2026 cohort study found that in utero exposure to levetiracetam and lamotrigine monotherapies was not associated with poorer neurocognitive outcomes in children aged 3–18 years compared to unexposed controls [289]C. However, maternal health during gestation significantly influences offspring risk; severe maternal morbidity (SMM) occurring between 20 weeks’ gestation and 42 days postpartum is associated with an increased risk of epilepsy diagnosis in the child [294].
Geriatrics and Late-Onset Epilepsy
Epilepsy in older adults (≥65 years) is categorized into early-onset persistent epilepsy (EOPE) and late-onset epilepsy (LOE). LOE is increasingly relevant in aging populations and may be bidirectionally associated with other neurologic conditions. For instance, older veterans with traumatic brain injury (TBI) show an increased incidence of epilepsy, while pre-existing epilepsy may also predispose individuals to TBI [299]. Furthermore, adult-onset hydrocephalus is linked to an increased hazard ratio for incident epilepsy [293]. In clinical practice, the use of sedatives like midazolam and propofol in the ICU can reduce the diagnostic yield of EEG for detecting epileptiform activity in patients with altered consciousness [287].
Health Disparities and Systemic Factors
Outcomes in epilepsy are influenced by geographic and socioeconomic factors. Rural residence in the United States is associated with disparities in clinical outcomes, likely due to limited access to specialized epilepsy centers and neurologists [277]. Additionally, tumor-related epilepsy, such as that seen in pleomorphic xanthoastrocytomas (PXAs), often presents with unrecognized focal seizures prior to diagnosis, emphasizing the need for early neurophysiologic evaluation [276].
| Medication | Age Group | Outcome Metric | Result |
|---|---|---|---|
| Perampanel | 7–46 months | 12-month Responder Rate | 47.4% [290] |
| Cenobamate | Pediatrics | Focal Seizure Reduction | Effective (Real-world) [301] |
| Cannabidiol | All Ages (DEE) | Seizure Frequency | Significant Reduction [285] |
Landmark Trials and Key Evidence
- ▸QuITT-SE baseline data focus on factors associated with rapid benzodiazepine treatment for acute pediatric and inpatient seizures, supporting time-to-treatment quality improvement. [323]
- ▸NAUTILUS is a randomized sham-controlled trial of bilateral centromedian thalamic responsive stimulation for drug-resistant idiopathic generalized epilepsy with generalized tonic-clonic seizures. [324]
- ▸Real-world responsive neurostimulation effectiveness is being evaluated over three years, with longer-term safety follow-up planned to five years. [268]
- ▸Pregnancy changes antiseizure-medication exposure and supports individualized concentration-to-dose monitoring, particularly during polytherapy. [327]
- ▸Ultra-long-term subcutaneous EEG provides an objective method for evaluating seizure-frequency changes after medication adjustments. [317]
- ▸FIRES cohorts associate longer therapeutic coma and greater treatment intensity with poorer functional outcome, but observational evidence does not prove causality. [333]
- ▸Genetic, imaging, EEG, and longitudinal cohort studies are refining prognosis in SCN2A disease, CDKL5 deficiency disorder, tubulinopathies, congenital CMV, and Down syndrome. [325] [330] [292] [332] [331]
Acute seizures and status epilepticus
Status epilepticus (SE) remains a time-critical neurological emergency, and the QuITT-SE program is evaluating whether implementation strategies can shorten the interval to benzodiazepine treatment. Its baseline cohort included 371 consecutive acute seizure episodes treated with a benzodiazepine in non-ICU inpatient settings, representing 207 patients across eight centers; the analysis examined clinical and demographic factors associated with prompt versus delayed treatment before the randomized stepped-wedge effectiveness-implementation phase. [323] In a separate multicenter prospective study of 521 patients with established epilepsy presenting with seizures to emergency departments across 34 Malaysian public hospitals, investigators assessed SE incidence, predictors, and in-hospital mortality, addressing the burden of SE in routine emergency care. [334]
FIRES represents a particularly severe form of refractory SE. A multicenter registry-based cohort of 93 children evaluated acute antiseizure medications and the duration and intensity of therapeutic coma in relation to long-term modified Rankin Scale outcomes; the study reported that longer therapeutic coma and more intensive treatment were associated with poorer functional outcome, although the observational design cannot establish causation. [333] In children with ischemic stroke, a prospective Chinese registry cohort included 562 patients aged 29 days to 18 years, of whom 137 had acute seizures, including 30 with SE and 68 with multiple seizures. The study examined associations between acute seizure patterns, antiseizure medication exposure, 90-day and 1-year functional outcomes, mortality, functional improvement, and poststroke epilepsy. [326]
Pharmacotherapy, monitoring, and rescue treatment
Pregnancy-related pharmacokinetic changes were examined prospectively in 947 women with epilepsy contributing 1,638 steady-state trough samples. The analysis used concentration-to-dose ratios and mixed-effects models to evaluate gestational age, concomitant antiseizure medications, and demographic covariates, providing evidence relevant to therapeutic-drug monitoring and polytherapy during pregnancy. [327] For intermittent treatment of seizure clusters, a post hoc analysis of a phase 3 open-label safety study of diazepam nasal spray in patients aged 6–65 years evaluated seizure interval (SEIVAL) as a potential effectiveness endpoint and assessed how study timing and participant characteristics influence its measurement. [315]
A first-in-disease phase 2A double-blind, randomized, dose-titration, crossover, placebo-controlled trial evaluated ES-481, a selective antagonist of TARP-γ8-dependent AMPA receptors, as add-on therapy in adults with drug-resistant epilepsy. Conducted across four Australian comprehensive epilepsy centers, the study assessed seizure-frequency change, safety, tolerability, pharmacokinetics, and anxiety and depressive symptom scores, followed by an open-label extension; 22 participants were randomized. [316] Ultra-long-term subcutaneous EEG was evaluated in a retrospective multicenter cohort of 65 adults with treatment-resistant epilepsy who contributed more than 280,000 hours of recording. The study compared EEG-derived seizure-frequency changes with seizure diaries after antiseizure medication dose increases or reductions over 7-, 14-, and 30-day windows. [317]
Neuromodulation and epilepsy surgery
The randomized, sham-controlled NAUTILUS pivotal trial evaluated bilateral centromedian thalamic responsive stimulation in patients aged ≥12 years with drug-resistant idiopathic generalized epilepsy and at least two generalized tonic-clonic seizures during a 3-month baseline. After implantation, 87 participants were randomized to active stimulation (44) or sham stimulation (43); the effectiveness evaluation began three months after implantation and continued through one year, with transition to open-label stimulation after a second generalized tonic-clonic seizure during the evaluation period. [324]
Real-world outcomes of responsive neurostimulation for drug-resistant focal epilepsy were assessed in an FDA-required prospective, open-label postapproval study across 32 U.S. epilepsy centers. The interim analysis enrolled 324 adults meeting the approved indication, with median percentage seizure-frequency change at three years as the primary effectiveness endpoint; interim safety was reported, while the primary safety endpoint was planned for five years. [268] In drug-resistant temporal lobe epilepsy, a prospective six-center cohort used preoperative diffusion MRI and resting-state functional MRI to derive structural and functional connectomes and test whether disruption of normative highly connected brain hubs predicts long-term seizure recurrence after resection or laser ablation. Participants had more than two years of follow-up, with a mean follow-up of 5.4 years. [311]
Diagnostic and treatment-related EEG evidence
A retrospective analysis of the randomized CERTA trial included 364 adults with acute disorders of consciousness, of whom 246 (67.6%) received sedative medication. It examined whether midazolam and propofol exposure and dose affected EEG detection of epileptiform abnormalities by comparing continuous EEG with two routine EEG recordings. [287]
Genetic, developmental, and syndromic epilepsies
A systematic review and retrospective multicenter cohort characterized MRI findings across SCN2A disease, including self-limited familial neonatal-infantile epilepsy and severe developmental and epileptic encephalopathies. Blinded pediatric neuroradiologists evaluated MRI studies from the SCN2A Natural History Study and an international cohort to examine abnormality frequency, evolution, and prognostic relevance. [325] Longitudinal EEG and clinical data from 48 infants and young children with CDKL5 deficiency disorder included 152 EEGs during the first 24 months, addressing the evolution of ictal and interictal abnormalities and their relationship with development. [330]
A Turkish multicenter cohort of 15 children from 12 unrelated families with genetically confirmed tubulinopathies identified variants across seven tubulin-related genes and evaluated seizure and neuroradiologic heterogeneity. [292]C In congenital cytomegalovirus infection, a registry study of 570 children from 11 countries developed the cCMVnet prognostic score for long-term sequelae, including epilepsy, using early imaging and clinical predictors. [332] In adults with Down syndrome, a multicohort longitudinal study examined epilepsy development, its timing relative to Alzheimer disease symptoms, and clinical prognosis, including late-onset myoclonic epilepsy in Down syndrome. [331]
Comorbidities, etiologic risk, and emerging therapies
A 49,925-patient multinational retrospective cohort examined gabapentin exposure and cognitive impairment after traumatic brain injury, stratifying adults by initial Glasgow Coma Scale severity and adjusting time-to-event analyses for known predictors. [328]C A combined Mendelian-randomization and multicenter cohort investigation evaluated whether serum uric acid is causally related to epilepsy susceptibility and whether it improves prediction of poststroke epilepsy beyond established factors; the cohort included 21,459 patients with acute ischemic stroke. [312]
A first-in-human prospective open-label cohort studied washed microbiota transplantation in 21 patients with epilepsy, using ≥50% seizure-frequency reduction at one month as the primary response endpoint and parallel pentylenetetrazole mouse experiments to investigate potential mechanisms involving core bacterial species. [329] These findings remain preliminary because of the small, single-center, nonrandomized design. [329]
| Domain | Study design and population | Main evidence focus |
|---|---|---|
| Acute SE treatment | QuITT-SE baseline cohort; 371 episodes, 207 patients, eight centers | Factors associated with rapid benzodiazepine treatment [323] |
| Thalamic stimulation | Randomized sham-controlled NAUTILUS trial; 87 randomized participants | Responsive stimulation for drug-resistant idiopathic generalized epilepsy [324] |
| Focal epilepsy neuromodulation | Prospective postapproval cohort; 324 adults, 32 U.S. centers | Three-year seizure outcomes and interim safety of responsive neurostimulation [268] |
| Medication monitoring | Prospective pregnancy cohort; 947 women, 1,638 samples | Gestational and polytherapy-related pharmacokinetic changes [327] |
| EEG monitoring | Multicenter cohort; 65 adults and >280,000 recording hours | Subcutaneous EEG assessment after medication changes [317] |
| Emerging therapy | Phase 2A ES-481 trial; 22 randomized participants | Add-on efficacy, tolerability, pharmacokinetics, and psychiatric outcomes [316] |
Guidelines and Resources
- ▸Valproate should be avoided in pregnancy due to high risks of major congenital malformations and cognitive impairment.
- ▸Prophylactic ASMs are not recommended for patients with brain tumors who have not had a seizure.
- ▸Lamotrigine, levetiracetam, and carbamazepine are preferred first-line monotherapies for focal epilepsy.
- ▸ASM tapering after 2 years of seizure freedom in adults doubles the recurrence risk (15% vs 7%).
- ▸Psychological interventions are the primary treatment for functional seizures.
- ▸Structural MRI is essential for infants with new-onset epilepsy due to high rates of structural abnormalities.
Clinical Practice Guidelines for Antiseizure Medication (ASM)
The management of epilepsy is guided by evidence-based protocols from the American Academy of Neurology (AAN), the International League Against Epilepsy (ILAE), and the American Epilepsy Society (AES). For patients with new-onset focal epilepsy, lamotrigine is recommended (Level B), while levetiracetam and zonisamide are also established options [217]. In pediatric and adult populations with focal onset seizures, carbamazepine, lamotrigine, or levetiracetam are recommended as first-line monotherapy [222]. While oxcarbazepine is an alternative for children, its evidence level varies [222]. For generalized tonic-clonic seizures, data on the efficacy of third-generation ASMs remain limited [217].
Management in Special Populations
Pregnancy and Childbearing Potential
Updated 2024 guidelines emphasize the risks of in utero exposure to ASMs. Valproate (VPA) exposure in the first trimester carries a significantly higher risk of major congenital malformations (MCMs) compared to carbamazepine, and likely higher than phenytoin or lamotrigine [215], [233]. Polytherapy further increases the risk of MCMs and reduced cognitive outcomes compared to monotherapy [233]. Preconceptional folic acid supplementation is possibly effective in reducing MCM risk [231]. Regarding obstetric outcomes, there is no substantially increased risk (>2 times expected) of cesarean delivery or late pregnancy bleeding for women with epilepsy [232]. While primidone and levetiracetam transfer into breast milk, the clinical impact on infants requires careful monitoring [231].
Brain Tumors and Cavernomas
In patients with newly diagnosed brain tumors who have not experienced a seizure, clinicians should not routinely prescribe prophylactic ASMs to reduce the risk of a first seizure [220]. For cavernoma-related epilepsy (CRE), surgical resection is a primary consideration, though seizure freedom is achieved in only approximately 75% of cases, often due to inadequate definition of the epileptogenic zone [224].
Diagnostic and Monitoring Standards
Neuroimaging and EEG
Structural MRI is recommended for infants (1–24 months) presenting with a first afebrile seizure or new-onset epilepsy, as structural abnormalities are frequent in this age group [302]. In older pediatric populations, nearly 50% of imaging studies in localization-related epilepsy are abnormal, with 2–4% providing information that immediately alters medical management [221]. Minimum standards for routine and sleep EEG have been established by the IFCN and ILAE to ensure diagnostic consistency [218].
Therapeutic Drug Monitoring (TDM)
While randomized studies are lacking, TDM is clinically valuable for establishing an individual's therapeutic concentration once a desired clinical outcome is reached [216]. It is particularly indicated when assessing changes in drug response, suspected toxicity, or adherence [216].
Long-term Management and Withdrawal
ASM Withdrawal
In adults who have been seizure-free for 2 years, the risk of recurrence after tapering ASMs is approximately 15%, compared to 7% in those who continue medication [219]. In pediatric patients, there is no significant difference in recurrence risk between tapering after 2 years versus 4 years of seizure freedom [219].
Functional Seizures
Management of functional (psychogenic non-epileptic) seizures should prioritize psychological interventions, which are possibly effective in increasing seizure freedom, reducing anxiety, and improving psychosocial functioning [226].
Wearable Technology
Automated seizure detection using wearable devices is now recommended for outpatient and ambulatory settings to improve seizure frequency tracking and safety [227], [228].
| Seizure Type | Recommended ASMs | Evidence Level |
|---|---|---|
| New-onset Focal (Adult) | Lamotrigine, Levetiracetam, Zonisamide | Level B [217] |
| Focal Monotherapy (Pediatric) | Carbamazepine, Lamotrigine, Levetiracetam | Strong [222] |
| Focal Monotherapy (Alternative) | Oxcarbazepine | Level A/C [222] |
References
- [1]
Balestrini S, Scheffer IE. “Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies.” CNS drugs (2026). PMID: 41712149 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [2]
Oka T, Okubo R, Motomura E et al.. “Emerging Role of Tripartite Synaptic Transmission in the Pathomechanism of Autosomal-Dominant Sleep-Related Hypermotor Epilepsy.” International journal of molecular sciences (2025). PMID: 41096936 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [3]
Yang J, Li L, Xu Y et al.. “TREK-1 and epilepsy: regulating the balance of K+ and the glutamate release in astrocyte-neuron interactions.” Behavioral and brain functions : BBF (2025). PMID: 40887605 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [4]
Magloire V, de Curtis M, Noebels J et al.. “WONOEP XVII appraisal: Targeting network excitability beyond the synapse -Neurotransmitter, ionic, and electro -diffusions.” Epilepsia (2025). PMID: 40682588 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [5]
Lee HA, Kim SW, Choi S et al.. “Neonatal-onset epileptic encephalopathy with lissencephaly associated with a SCN3A variant: The first case in Korea and literature review.” Seizure (2026). PMID: 41643417 ↗
L4CASE_REPORTCited in: Pathophysiology - [6]
Dudley AM, Peña-Ceballos J, El-Naggar H et al.. “Dravet syndrome diagnosed in adults.” Practical neurology (2026). PMID: 41136202 ↗
L4CASE_REPORTCited in: Pathophysiology - [7]
Canafoglia L, Mastrangelo M, Russo M et al.. “Severe epilepsy phenotypes in adults with succinic semialdehyde dehydrogenase deficiency: Novel clinical and therapeutic insights from an Italian multicenter retrospective cohort study.” Seizure (2025). PMID: 40763422 ↗
L2bCOHORTCited in: Pathophysiology - [8]
Sangeeth TA, Viswanathan LG, Padmanabha H et al.. “KCTD7-related progressive myoclonic epilepsy: Clinical and genetic characterization of six Indian patients and review of literature.” Seizure (2026). PMID: 41564653 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [9]
Yazdi SM, Gomez AJ, Goldman A et al.. “The path to post-traumatic epilepsy: A review of emerging biomarkers and therapeutic targets.” Seizure (2025). PMID: 41187576 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [10]
Modgil A, Rana ZS, Sahu JK et al.. “Understanding the neurobiology of infantile epileptic spasms syndrome (IESS): A comprehensive review.” Seizure (2025). PMID: 41175509 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [11]
Kołba W, Herbst D, Szulczyk B. “Clonidine Inhibits Interictal-like Epileptiform Events in Prefrontal Cortex Pyramidal Neurons.” International journal of molecular sciences (2026). PMID: 41898583 ↗
L5OTHERCited in: Pathophysiology - [12]
Wengert ER, Liebergall SR, Jimenez T et al.. “Impaired excitability of fast-spiking neurons in a novel mouse model of KCNC1 epileptic encephalopathy.” eLife (2026). PMID: 41705663 ↗
L5OTHERCited in: Pathophysiology - [13]
Postnikova TY, Diespirov GP, Griflyuk AV et al.. “Minocycline-induced microglial remodeling restores hippocampal NMDA-dependent synaptic plasticity and reduces anxiety-like behavior in juvenile rats with temporal lobe epileptogenesis.” Life sciences (2026). PMID: 41513001 ↗
L5OTHERCited in: Pathophysiology - [14]
Yadav N, Priya, Dixit N et al.. “Altered Fibronectin-α5β1 Integrin-Src Signalling Pathway Drives Network Hyperexcitability in the Hippocampal Formation and Anterior Temporal Lobe in Temporal Lobe Epilepsy.” Neurochemical research (2026). PMID: 41499010 ↗
L5OTHERCited in: Pathophysiology - [15]
Huang JZ, Lu GF, Jiang YH et al.. “Prefrontal TRPM8 Receptor Modulates Epileptic Seizures via PKA/CREB Signaling Pathway in Mice.” CNS neuroscience & therapeutics (2026). PMID: 41474182 ↗
L5OTHERCited in: Pathophysiology - [16]
Gong Y, Zhang S, Fei F et al.. “Ventral subicular pyramidal neurons contribute to epileptogenesis via anterior thalamic circuit.” Communications biology (2025). PMID: 41454087 ↗
L5OTHERCited in: Pathophysiology - [17]
Costa C, Bellingacci L, Canonichesi J et al.. “Neuronal hyperexcitability: A key to unraveling hippocampal synaptic dysfunction in Lafora disease.” Epilepsia (2026). PMID: 41408964 ↗
L5OTHERCited in: Pathophysiology - [18]
Ortiz S, Bagliani C, Lin SXN et al.. “Early neurological symptoms and epilepsy outcomes in individuals with the recurrent GABRG2 p.(Ala106Thr) gain-of-function variant: Structural and phenotypic insights.” Epilepsia (2026). PMID: 41351427 ↗
L5OTHERCited in: Pathophysiology - [19]
Kharkhelauri L, Gamkrelidze G, Bokuchava V et al.. “Dose-Dependent Effects of Myo-Inositol on Kainic Acid-Induced Epilepsy: Electrophysiological, Behavioral, Transcriptomic, and DNA Methylome Studies.” International journal of molecular sciences (2025). PMID: 41303586 ↗
L5OTHERCited in: Pathophysiology - [20]
Sullivan J, Wirrell EC, Knupp KG et al.. “Natural History of Children and Adolescents With Dravet Syndrome: A 24-Month Follow-Up.” Neurology (2025). PMID: 41237355 ↗
L5OTHERCited in: Pathophysiology - [21]
Palmer D, Forcelli PA. “Restoring failed inhibition in the substantia nigra pars reticulata suppresses absence seizures in rats.” Epilepsia (2026). PMID: 41182510 ↗
L5OTHERCited in: Pathophysiology - [22]
Balestrini S, Galli I, Ricci ML et al.. “Clinical and genetic landscape of epilepsies with absence seizures and single-gene etiology.” Epilepsia (2026). PMID: 41137852 ↗
L5OTHERCited in: Pathophysiology - [23]
Wang Y, Liu M, Hua N et al.. “Delayed excitability recovery and downregulation of neurodevelopmental pathways contribute to phenotypic differences in KCNQ2-related disorders.” Epilepsia (2026). PMID: 41051877 ↗
L5OTHERCited in: Pathophysiology - [24]
Galer PD, McKee JL, Ruggiero SM et al.. “Quantitative EEG Biomarkers in the Genetic Epilepsies and Associations With Neurologic Outcomes.” Neurology (2025). PMID: 40986432 ↗
L5OTHERCited in: Pathophysiology - [25]
Ngoh A, Clark M, Greenaway R et al.. “Clinical and Molecular Genetic Characterization of Landau Kleffner Syndrome: An Observational Cohort and Experimental Study.” Annals of neurology (2025). PMID: 40944498 ↗
L5OTHERCited in: Pathophysiology - [26]
Howey C, McFetridge A, Luczak A. “Intermediate Stage of Epileptogenesis Is Not Affected by Disrupting Memory Consolidation Processes.” International journal of molecular sciences (2025). PMID: 40943279 ↗
L5OTHERCited in: Pathophysiology - [27]
Falck A, Lehnhoff J, Behbood M et al.. “Potassium-chloride cotransporter 2 activity dampens induced ictal-like activity in neocortical slices containing the seizure propagation zone of temporal lobe epilepsy patients.” Epilepsia (2026). PMID: 40932659 ↗
L5OTHERCited in: Pathophysiology - [28]
Milla BM, da Silva EN, Sobrinho CR et al.. “Developmental progression of respiratory dysfunction in a mouse model of Dravet syndrome.” JCI insight (2025). PMID: 40924494 ↗
L5OTHERCited in: Pathophysiology - [29]
Yuan Y, O'Malley HA, Winters JJ et al.. “Ataxia and cerebellar hypoexcitability in a mouse model of SCN1B-linked Dravet syndrome.” JCI insight (2025). PMID: 40923316 ↗
L5OTHERCited in: Pathophysiology - [30]
Hristova K, Fasol MCM, McLaughlin N et al.. “Absence seizures and sleep-wake abnormalities in a rat model of GRIN2B neurodevelopmental disorder.” Epilepsia (2025). PMID: 40827489 ↗
L5OTHERCited in: Pathophysiology - [31]
Chochoł P, Arturo N, Łajczak PM et al.. “Effects of Antiseizure Medications on Lipid Profile and Weight in Patients with Epilepsy: A Systematic Review with Meta-analysis.” CNS drugs (2025). PMID: 41032224 ↗
L2aSR_OBSCited in: History and Physical Examination - [32]
Shah SN, Fong HF, Haney SB et al.. “Has This Child Experienced Physical Abuse?: The Rational Clinical Examination Systematic Review.” JAMA (2025). PMID: 40257808 ↗
L2aSR_OBSCited in: History and Physical Examination - [33]
Zhu S, Zhu H, Liu X et al.. “Genotype-phenotype correlation of ODLURO syndrome comorbid epilepsy associated with KMT2E variations: Report on a novel case and systematic literature review.” Epilepsy & behavior : E&B (2025). PMID: 40048818 ↗
L2aSR_OBSCited in: History and Physical Examination - [34]
Jeppesen J, Christensen J, Ahrenfeldt Petersen O et al.. “Seizure detection using wearable electrocardiogram connected to a smartphone: a phase 3 clinical validation study.” EBioMedicine (2025). PMID: 41027311 ↗
L2bTRIAL_NONRANDOMCited in: History and Physical Examination - [35]
Pan W, Yu D, Mo J et al.. “Deficits in facial emotion recognition in temporal lobe epilepsy: Comprehensive understanding from cognitive neuroscience perspectives.” Journal of psychiatric research (2026). PMID: 41483726 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [36]
Chen J, Zhuo H, Rogne T et al.. “Maternal pre-pregnancy body mass index, gestational weight gain and epilepsy in the offspring: A population-based cohort study.” Epilepsy research (2026). PMID: 41762485 ↗
L2bCOHORTCited in: History and Physical Examination, Special Populations: Pediatrics, Pregnancy, and Geriatrics - [37]
Ju Y, Ji TY. “Electro-clinical features of Mowat-Wilson syndrome: A retrospective study of 31 children in mainland China.” Epileptic disorders : international epilepsy journal with videotape (2026). PMID: 41454799 ↗
L2bCOHORTCited in: History and Physical Examination, Clinical Features and Seizure Variants - [38]
Assmann M, Albrecht I, Frenser M et al.. “Database Analysis of Application Areas and Global Trends in Ketogenic Diets from 2019 to 2024.” Nutrients (2025). PMID: 40362787 ↗
L2aSR_OBSCited in: History and Physical Examination - [39]
Park PS, Chu DT, Bamford NS. “Clinical Reasoning: A 5-year-Old Boy With Subacute and Refractory Myoclonus.” Neurology (2026). PMID: 41337684 ↗
L4CASE_REPORTCited in: History and Physical Examination, Differential Diagnosis - [40]
Mohammad Alizadeh Chafjiri F, Dailey S, Sadeghian S et al.. “Antiseizure medication effects on the autonomic nervous system in pediatric patients with epilepsy.” Epilepsy research (2025). PMID: 41326262 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [41]
Alhaskir M, Kutafina E, Linke F et al.. “Reliable detection of focal onset impaired awareness seizures in patients with epilepsy using wearable ECG: Development and validation study.” Computer methods and programs in biomedicine (2026). PMID: 41764784 ↗
L5OTHERCited in: History and Physical Examination, Diagnosis and Workup, Special Populations: Pediatrics, Pregnancy, and Geriatrics, Landmark Trials and Key Evidence - [42]
Li Y, Pan NC, Xu C et al.. “Distinct Subdivisions of the Cingulo-Insular Region and Their Role in Modulating the Cardiac Sympathetic-Parasympathetic Balance.” Circulation. Arrhythmia and electrophysiology (2026). PMID: 41725548 ↗
L5OTHERCited in: History and Physical Examination, Diagnosis and Workup - [43]
Qin X, Zhao W, Chen S et al.. “Validates blood pressure control for seizure management: Jujuboside B exerts antiseizure effects via blood pressure reduction and activation of NTS-VGLUT2+ neurons.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 41655550 ↗
L5OTHERCited in: History and Physical Examination - [44]
Çoban DS, Çalışkan N, Ünalp A et al.. “Evaluation of thyroid function and thyroid volume in pediatric epileptic patients receiving levetiracetam monotherapy.” European journal of pediatrics (2026). PMID: 41582223 ↗
L5OTHERCited in: History and Physical Examination - [45]
Gravitis AC, Wennberg R, Carlen PL et al.. “Cardiorespiratory cross-frequency coupling biomarker for sudden unexpected death in epilepsy.” Epilepsia (2026). PMID: 41389016 ↗
L5OTHERCited in: History and Physical Examination - [46]
Yang H, Zhang Q, Huang K et al.. “More Fixations in Static Facial Regions During Emotion Recognition Among TLE Patients With Severe Depression.” CNS neuroscience & therapeutics (2025). PMID: 41159311 ↗
L5OTHERCited in: History and Physical Examination - [47]
Villamor E, Miglin AK, Cnattingius S. “Grandmaternal Obesity and Risks of Birth Asphyxia-Related Complications in Grand-Offspring: A Countrywide Three-Generation Study.” Obesity (Silver Spring, Md.) (2025). PMID: 40964798 ↗
L5OTHERCited in: History and Physical Examination - [48]
Nouboue C, Diab E, Gacquer W et al.. “Heart rate variability-based detection of epileptic seizures: Machine learning analysis and characterization of discriminant metrics.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2025). PMID: 40561720 ↗
L5OTHERCited in: History and Physical Examination - [49]
Wang X, Yang H, Cheng Y et al.. “Mapping human brain topography to heart rhythms: an SEEG study.” Cardiovascular research (2025). PMID: 40469003 ↗
L5OTHERCited in: History and Physical Examination - [50]
Nasseri M, Stirling RE, Viana PF et al.. “Forecasting epileptic seizures with wearable devices: A hybrid short- and long-horizon pseudo-prospective approach.” Epilepsia (2025). PMID: 40411751 ↗
L5OTHERCited in: History and Physical Examination - [51]
Smith BC, Thornton C, Stirling RE et al.. “More variable circadian rhythms in epilepsy captured by long-term heart rate recordings from wearable sensors.” Epilepsia (2025). PMID: 40286232 ↗
L5OTHERCited in: History and Physical Examination - [52]
Müller SJ, Khadhraoui E, Kukhlenko O et al.. “Brain Volume Loss After Stereotactic Laser Interstitial Thermal Therapy in Patients With Temporal Lobe Epilepsy.” Journal of neuroimaging : official journal of the American Society of Neuroimaging (2025). PMID: 40197718 ↗
L5OTHERCited in: History and Physical Examination - [53]
Zhuravlev D, Marchenko A, Skalnaya A et al.. “Ictal cardiovascular autonomic dysfunction during focal seizures induced by direct electrical stimulation: An observational study research protocol.” PloS one (2025). PMID: 40163436 ↗
L2bTRIAL_NONRANDOMCited in: History and Physical Examination - [54]
Inoue T, Nomura S, Yamakawa T et al.. “Intraoperative evaluation using a multimodality probe of temperature-dependent neurovascular modulation during focal brain cooling.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2025). PMID: 40073587 ↗
L5OTHERCited in: History and Physical Examination - [55]
Eilbes M, Gallo A, Osmani WA et al.. “Unique features of seizure-induced cardiorespiratory failure in SSKcnj16-/- rats: Implications for sudden unexpected death in epilepsy.” Epilepsia (2025). PMID: 40067249 ↗
L5OTHERCited in: History and Physical Examination - [56]
Premachandran S, Ocay DD, Beaulieu C et al.. “Pain experience of children with Christianson syndrome.” Pain (2025). PMID: 39945731 ↗
L5OTHERCited in: History and Physical Examination - [57]
Konomatsu K, Kakisaka Y, Jin K et al.. “Adult-onset epilepsy with startle-induced seizure after febrile infection-related epilepsy syndrome: A case report.” Epileptic disorders : international epilepsy journal with videotape (2025). PMID: 40232152 ↗
L4CASE_REPORTCited in: History and Physical Examination - [58]
Gagaouzova BS, van Rossum IA, van Hoey Smith J et al.. “Novel insights regarding haemodynamics in focal seizures.” Epilepsy research (2025). PMID: 39979000 ↗
L4CASE_REPORTCited in: History and Physical Examination - [59]
Li J, Nurse ES, Grayden DB et al.. “Epileptic seizure detection using heart rate variability from ambulatory ECG: a pseudoprospective study.” Journal of neural engineering (2025). PMID: 40112456 ↗
L2bCOHORTCited in: History and Physical Examination - [60]
Kalita J, Nizami FM, Dubey AK et al.. “Safety and efficacy of vigabatrin add on compared to placebo in Lennox-Gastaut syndrome (LennoVig): A single center randomized double-blind placebo-controlled trial.” Journal of the neurological sciences (2026). PMID: 41500178 ↗
L1bRCTCited in: Clinical Features and Seizure Variants - [61]
Yu P, Wu X, Cui L et al.. “Efficacy and Safety of Adjunctive Cenobamate in Chinese Participants with Focal Seizure.” Advances in therapy (2026). PMID: 41428177 ↗
L1bRCTCited in: Clinical Features and Seizure Variants, Landmark Trials and Key Evidence - [62]
Peña-Ceballos J, Moloney PB, Kinney MO et al.. “How are we doing? The electroclinical diagnosis of status epilepticus in idiopathic generalized epilepsy in a tertiary referral center: A case series and scoping review of 40 years of literature.” Journal of the neurological sciences (2026). PMID: 41807915 ↗
L4CASE_REPORTCited in: Clinical Features and Seizure Variants, Diagnosis and Workup - [63]
Wang P, Lu L, Gao H et al.. “Will Memantine Exacerbate Seizures in People With Epilepsy? A Prospective Cohort Study.” Annals of clinical and translational neurology (2026). PMID: 41288262 ↗
L2bCOHORTCited in: Clinical Features and Seizure Variants - [64]
Peng W, Lu L, Yin J et al.. “Factors associated with long-term outcomes in people with new onset refractory epilepticus: A single-center cohort study.” Epilepsia (2026). PMID: 41277767 ↗
L2bCOHORTCited in: Clinical Features and Seizure Variants - [65]
Rosenfeld WE, Ferrari L. “Wide range of cenobamate doses associated with initial seizure freedom in patients with uncontrolled focal seizures: Post-hoc analysis of a phase 3, multicenter, open-label study.” Epilepsy & behavior : E&B (2026). PMID: 41386196 ↗
L2bTRIAL_NONRANDOMCited in: Clinical Features and Seizure Variants, Landmark Trials and Key Evidence - [66]
Breuer E, Vorderwülbecke BJ, Holtkamp M. “Idiopathic generalised epilepsies in 2026.” Current opinion in neurology (2026). PMID: 41589711 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Seizure Variants - [67]
Wang L, Liu Y, Ding W et al.. “Carbogen Inhalation Therapy for Epileptic Seizures: Mechanisms, Evidence, and Future Directions.” CNS neuroscience & therapeutics (2025). PMID: 41342230 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Seizure Variants - [68]
Ryvlin P, Huot M, Valton L et al.. “Seizure-related biomarkers of sudden unexpected death in epilepsy (SUDEP) in drug-resistant focal epilepsy (REPO2MSE): a prospective, multicentre case-control study.” The Lancet. Neurology (2026). PMID: 41285145 ↗
L3bCASE_CONTROLCited in: Clinical Features and Seizure Variants, Landmark Trials and Key Evidence - [69]
Surí-Báez C, Kim HJ, Lester J et al.. “Beyond Anakinra and Tocilizumab: Additional Adjunctive Therapies in Pediatric New Onset Refractory Status Epilepticus and Febrile Infection-Related Epilepsy Syndrome - A Narrative Review.” Pediatric neurology (2026). PMID: 41265024 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Seizure Variants - [70]
Yoo JY, Bloomfield J, Eka O et al.. “Vagus nerve stimulation as an adjunctive therapy for super-refractory status epilepticus including NORSE: a retrospective cohort study.” Epilepsy & behavior : E&B (2026). PMID: 41875755 ↗
L2bCOHORTCited in: Clinical Features and Seizure Variants, Special Populations: Pediatrics, Pregnancy, and Geriatrics - [71]
Zajączkowski M, Klasa Ł, Kwiatkowski S et al.. “Therapies of last resort in paediatric super-refractory status epilepticus: a case report on combined selective amygdalohippocampectomy, vagus nerve stimulation, and anterior corpus callosotomy.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2026). PMID: 41739236 ↗
L4CASE_REPORTCited in: Clinical Features and Seizure Variants - [72]
Gburek-Augustat J, Lee IC, Rubino M et al.. “Sialidosis type I: How to alleviate disabling myoclonic seizures?-A multicenter analysis of eight cases and review of the literature.” Epilepsia open (2026). PMID: 41665440 ↗
L4CASE_REPORTCited in: Clinical Features and Seizure Variants - [73]
Yan X, He J, Cheng M et al.. “Efficacy differences between tocilizumab and ketogenic diet during acute phase of febrile Infection-Related epilepsy syndrome in children: A retrospective cohort study.” Epilepsy & behavior : E&B (2026). PMID: 41633319 ↗
L2bCOHORTCited in: Clinical Features and Seizure Variants - [74]
Lee J, Choi A, Kim S et al.. “Effects of vagus nerve stimulation and epilepsy surgery on antiseizure medication usage in pediatric patients with drug-resistant epilepsy in the real world: A retrospective nationwide cohort study.” Epilepsia open (2026). PMID: 41416994 ↗
L2bCOHORTCited in: Clinical Features and Seizure Variants, Surgical and Interventional Management - [75]
Bui AH, Le VKT, Tang HK. “Incidence and clinical predictors of epilepsy after febrile seizures in children: A prospective cohort study in Vietnam.” Epilepsia open (2026). PMID: 41409019 ↗
L2bCOHORTCited in: Clinical Features and Seizure Variants - [76]
Zhang J, Wang X, Rao X et al.. “Clinical Characteristics and Treatment Outcomes in Children With Non-Acquired Epilepsy: A Cohort Study Based on Genetic Findings.” Clinical genetics (2026). PMID: 41373166 ↗
L2bCOHORTCited in: Clinical Features and Seizure Variants - [77]
Zeng Y, Zeng Q, Peng X et al.. “Efficacy, safety, and predictors of vagus nerve stimulation in children with drug-resistant epilepsy: A single-center prospective study.” Clinical neurology and neurosurgery (2026). PMID: 41349421 ↗
L2bCOHORTCited in: Clinical Features and Seizure Variants - [78]
Das NB, Haq MZU, Anwar E et al.. “Safety and Efficacy of Eslicarbazepine Acetate in Children Diagnosed With a Focal Seizure Disorder: A Systematic Review and Meta-Analysis.” Brain and behavior (2025). PMID: 41287184 ↗
L2aSR_OBSCited in: Clinical Features and Seizure Variants - [79]
Tonkin JY, Taylor L, Macdonald-Laurs E. “Cerebral Cavernous Malformations Presenting With Epileptic Spasms in Children.” Pediatric neurology (2026). PMID: 41477988 ↗
L4CASE_REPORTCited in: Clinical Features and Seizure Variants - [80]
Koepp MJ, Poppert KN, Felder T et al.. “Intranasal Seletracetam in a Patient with Reading Epilepsy: First-in-Human Use to Prevent Reflex Seizures.” Annals of neurology (2026). PMID: 41459805 ↗
L4CASE_REPORTCited in: Clinical Features and Seizure Variants - [81]
Tang M, Bai A, Ferreira FRM et al.. “Refractory Status Epilepticus Treated With Bilateral Pulvinar Deep Brain Stimulation-A Case Study.” Annals of clinical and translational neurology (2026). PMID: 41345856 ↗
L4CASE_REPORTCited in: Clinical Features and Seizure Variants - [82]
Paolicchi JM, Matchanov OA. “EEG findings in Lennox-Gastaut syndrome: Pursuing a moving target.” Seminars in pediatric neurology (2026). PMID: 41962993 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Seizure Variants - [83]
Mastrangelo M, Bonaventura CD, Lentini G et al.. “An updated overview on clinical and developmental trajectories of developmental and epileptic encephalopathies: From childhood to adulthood.” Seizure (2026). PMID: 41421304 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Seizure Variants - [84]
Sankar R, Ferrari L, Kamin M. “Exploration of the mechanism of action of cenobamate.” Seizure (2026). PMID: 41285102 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Seizure Variants - [85]
Morais TP, Bombardi C, Crunelli V et al.. “Circuit-Selective FAAH Inhibition Suppresses Experimental Absence Seizures.” CNS neuroscience & therapeutics (2026). PMID: 41969140 ↗
L5OTHERCited in: Clinical Features and Seizure Variants - [86]
Marini C, Rosati A, Fusco L et al.. “Genetic Etiologies of Epilepsies With Status Epilepticus: Insights From the Italian Pediatric Status Epilepticus Group Cohort.” Neurology (2026). PMID: 41915870 ↗
L5OTHERCited in: Clinical Features and Seizure Variants, Special Populations: Pediatrics, Pregnancy, and Geriatrics, Landmark Trials and Key Evidence - [87]
Yang H, Wang W, Liu X et al.. “STING Mediates Microglial Polarization to Promote Neuroinflammation in Epilepsy-Related Cognitive Dysfunction.” Neurochemical research (2026). PMID: 41880095 ↗
L5OTHERCited in: Clinical Features and Seizure Variants - [88]
Sala Padró J, Fonseca E, Quintana M et al.. “Impact of Treatment Delays in Epileptic Seizures: Time to Hospital Care and to EEG Increases Risk of Status Epilepticus and ICU Admission in Epileptic Seizures.” European journal of neurology (2026). PMID: 41778530 ↗
L5OTHERCited in: Clinical Features and Seizure Variants, Diagnosis and Workup, Special Populations: Pediatrics, Pregnancy, and Geriatrics - [89]
Liang S, Fan X, Kuang S et al.. “Clinical practice guidelines for the diagnosis and treatment of diffuse glioma-related epilepsy: 2025 update.” Cancer letters (2026). PMID: 41740829 ↗
L1cGUIDELINECited in: Diagnosis and Workup - [90]
De Dominicis A, Mercier M, Carfi Pavia G et al.. “Early Clinical and EEG Association of Genotype and Outcome in Genetic Epilepsies: A Cohort Study and Hierarchical Clustering Analysis.” Neurology (2026). PMID: 41818656 ↗
L2bCOHORTCited in: Diagnosis and Workup, Special Populations: Pediatrics, Pregnancy, and Geriatrics - [91]
Wang Z, Huang J, Chen M et al.. “Diagnosis of the first seizure-like events in children from third-tier cities in southwestern China: a retrospective cohort study.” BMJ paediatrics open (2026). PMID: 41698700 ↗
L2bCOHORTCited in: Diagnosis and Workup - [92]
Koutsouvelis P, Ermans SJE, Volmer L et al.. “Localizing the epileptogenic zone using deep learning and neuroimaging: A systematic review.” Seizure (2026). PMID: 41833257 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [93]
Alsini H, Al-Otaibi A, Khan IA et al.. “Exploring the clinical, neuroimaging, and genetic spectrum of PLPBP deficiency: multicenter case series and systematic review.” Molecular genetics and metabolism (2026). PMID: 41671913 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [94]
. “[Electroencephalography. Guidelines].” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2026). PMID: 41919630 ↗
L1cGUIDELINECited in: Diagnosis and Workup - [95]
Sinkin MV, Aleksandrova TA, Baranova EA et al.. “[Guidelines for clinical electroencephalography: Russian professional community development and consensus building].” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2026). PMID: 41919629 ↗
L1cGUIDELINECited in: Diagnosis and Workup - [96]
B Szabo A, Curot J, Gérard F et al.. “Refining Detection of Subclinical Epileptiform Activity in Alzheimer's Disease: A Case-Control Study and Call for a Consensus.” Annals of neurology (2026). PMID: 41669802 ↗
L3bCASE_CONTROLCited in: Diagnosis and Workup - [97]
Zhang LB, Wu YY, Qiu DJ et al.. “Child Neurology: Multiple Genetic Etiologies Causing Dandy-Walker Variant With Microcephaly, Epilepsy, and Global Developmental Delay.” Neurology (2026). PMID: 41791021 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [98]
Wan L, Cao X, Wang W et al.. “Efficacy and tolerability of early assessment of epileptic spasms to guide sequential treatment in children with infantile epileptic spasms syndrome:A nested case-control Study.” Seizure (2026). PMID: 41797007 ↗
L3bCASE_CONTROLCited in: Diagnosis and Workup, Special Populations: Pediatrics, Pregnancy, and Geriatrics - [99]
Ahmad IM, Ashar B, Munir S et al.. “A hybrid deep learning framework for epileptic seizure prediction using scalp and intracranial EEG data.” Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society (2026). PMID: 41905025 ↗
L5OTHERCited in: Diagnosis and Workup - [100]
Öhl N, Strack D, Kusnik SM et al.. “Challenges of Standard Pediatric Epilepsy Monitoring and the Potential Benefits of Contactless Sensor Technologies: Exploratory Qualitative Study.” Journal of medical Internet research (2026). PMID: 41875430 ↗
L5OTHERCited in: Diagnosis and Workup, Special Populations: Pediatrics, Pregnancy, and Geriatrics - [101]
Okazaki Y, Hayashi T, Iijima K et al.. “Transition from Subdural Electrocorticography to Stereo-electroencephalography in Presurgical Evaluation of Epilepsy: Single-institutional Experience.” Neurologia medico-chirurgica (2026). PMID: 41765449 ↗
L5OTHERCited in: Diagnosis and Workup, Surgical and Interventional Management, Special Populations: Pediatrics, Pregnancy, and Geriatrics - [102]
Hu Z, Yi R, Li Y et al.. “Multi-scale kernel and electrode attention network for EEG-based epileptic seizure detection.” Computers in biology and medicine (2026). PMID: 41747565 ↗
L5OTHERCited in: Diagnosis and Workup - [103]
Yang S, Xia J, Liao W et al.. “Linking Cortical Morphometry in Self-Limited Epilepsy With Centrotemporal Spikes to Cognition, Function, and Molecular Architecture.” CNS neuroscience & therapeutics (2026). PMID: 41725458 ↗
L5OTHERCited in: Diagnosis and Workup, Landmark Trials and Key Evidence - [104]
Wemheuer L, Doll A, Wegrzyn M et al.. “Default Mode Network Resting State Connectivity Derived From Task-Based fMRI: A Validation Study in People With Epilepsy.” Journal of neuroimaging : official journal of the American Society of Neuroimaging (2026). PMID: 41721540 ↗
L5OTHERCited in: Diagnosis and Workup - [105]
Zhao H, Zhang B, He Q et al.. “The Dual Associations of Peripheral Inflammatory Cells With Brain Reorganization in Insular Gliomas With/Without Epilepsy: An Exploratory Analysis.” CNS neuroscience & therapeutics (2026). PMID: 41721208 ↗
L5OTHERCited in: Diagnosis and Workup - [106]
Adler S, Wagstyl K. “AI in epilepsy neuroimaging.” Current opinion in neurology (2026). PMID: 41715296 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [107]
Millevert C, Vidas-Guscic N, Adhikari MH et al.. “Imaging brain development in a KCNQ2-developmental and epileptic encephalopathy mouse model: identifying early biomarkers for functional and structural brain changes.” EBioMedicine (2025). PMID: 41705898 ↗
L5OTHERCited in: Diagnosis and Workup - [108]
Zanuttini L, Pasini E, Ferri L et al.. “Integration of intraoperative ultrasound and depth-electrode electrocorticography for resection guidance in epilepsy surgery: technical workflow and feasibility.” Acta neurochirurgica (2026). PMID: 41697465 ↗
L5OTHERCited in: Diagnosis and Workup, Surgical and Interventional Management - [109]
Na JH, Lee YM. “Unraveling Lennox-Gastaut Syndrome: From Molecular Pathogenesis to Precision Diagnosis and Targeted Therapy Evolving Therapeutic Strategies.” International journal of molecular sciences (2026). PMID: 41683806 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [110]
Ciumas C, Bouet R, Rossetti AO et al.. “Brainstem Respiratory Center Dysfunction in Persons With Epilepsy: An fMRI Study.” Neurology (2026). PMID: 41666341 ↗
L5OTHERCited in: Diagnosis and Workup - [111]
Yamaguchi T, Uehara T, Okadome T et al.. “Scalp Electroencephalography Markers of Hidden Interictal Epileptiform Discharges in the Mesial Temporal Lobe.” International journal of neural systems (2026). PMID: 41663307 ↗
L5OTHERCited in: Diagnosis and Workup - [112]
Lee MH, Xiao B, Banerjee S et al.. “ESM-AnatTractNet: Advanced deep learning model of true positive eloquent white matter tractography to improve preoperative evaluation of pediatric epilepsy surgery.” Medical image analysis (2026). PMID: 41638061 ↗
L5OTHERCited in: Diagnosis and Workup - [113]
Xiao T, Nie C, Feng W et al.. “Epileptic Seizure Detection from EEG Signals with Long Short-Term Memory-Transformer and Self-Supervised Learning.” International journal of neural systems (2026). PMID: 41633930 ↗
L5OTHERCited in: Diagnosis and Workup - [114]
Sánchez-Hernández SE, Salido-Ruiz RA, Santos-Arce SR et al.. “Analysis of EEG univariate features for epileptic seizures.” Computers in biology and medicine (2026). PMID: 41633274 ↗
L5OTHERCited in: Diagnosis and Workup - [115]
Zhang Y, Zeng GQ, Lu R et al.. “The diagnostic value of sleep-deprived EEG in epilepsy: A meta-analysis.” Seizure (2024). PMID: 39236599 ↗
L2aSR_OBSCited in: Differential Diagnosis - [116]
De Giorgis V, Varesio C, Celario M et al.. “A prospective randomized crossover trial investigating melatonin versus sleep deprivation for sleep induction in nap electroencephalography.” Epilepsia open (2026). PMID: 41208640 ↗
L1bRCTCited in: Differential Diagnosis - [117]
Fan L, Zhao J. “A Child with Epileptic Seizure: A Case of Significantly Enhanced MVNT.” Clinical neuroradiology (2026). PMID: 41196317 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [118]
Lu Y, Ge Y, Wang R et al.. “Familial adult myoclonus epilepsy: A comprehensive diagnostic strategy for clinical practice.” Epilepsia (2025). PMID: 40747611 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [119]
Krishnamurthy KB. “Epilepsy.” Annals of internal medicine (2025). PMID: 40194289 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [120]
Fotedar N, Lüders HO. “Nocturnal paroxysmal dystonia to sleep-related hypermotor epilepsy: A critical review.” Epilepsia (2024). PMID: 39046177 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [121]
Soker EB, Erdem M, Ozdogru D et al.. “The role of serum biomarkers in differential diagnosis of epileptic seizures, functional/cognitive seizure and syncope: A prospective cohort study.” Clinical neurology and neurosurgery (2025). PMID: 40885038 ↗
L2bCOHORTCited in: Differential Diagnosis - [122]
Gasparini S, Giussani G, Bianchi E et al.. “Utility and limitations of homemade videos in differentiating functional seizures from other paroxysmal events: An Italian cohort study.” Epilepsia open (2025). PMID: 40292485 ↗
L2bCOHORTCited in: Differential Diagnosis - [123]
Chumbley LB, Denkensohn C, Cook GA et al.. “Clinical Reasoning: A 21-Year-Old Patient Presenting With Penile Hemidystumescence.” Neurology (2026). PMID: 41411604 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [124]
Gupta G, O'Brien LM, Hassan F et al.. “Feasibility of sleep assessment modalities in children with Lennox-Gastaut syndrome.” Seminars in pediatric neurology (2025). PMID: 41371875 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [125]
Hsu TR, Chen PH, Lin WS. “Astrocytic Biomarkers in Epilepsy: A Critical Review on Clinical Utility and Mechanistic Implications.” Frontiers in bioscience (Landmark edition) (2025). PMID: 41074428 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [126]
Möller L, Jünemann C, Claudi C et al.. “[Leading symptom: motor manifestations with impaired consciousnes : Management of epileptic seizures and status epilepticus].” Medizinische Klinik, Intensivmedizin und Notfallmedizin (2025). PMID: 39729154 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [127]
Binaghi E, Schwab N, Capecchi F et al.. “EEG variability in inflammatory encephalopathy: Dissemination in time and space.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2025). PMID: 41177133 ↗
L5OTHERCited in: Differential Diagnosis - [128]
Burani M, Giovannini G, Orlandi N et al.. “Peri-ictal respiratory dysfunction: Expanding the association between mTOR pathway disorders and ictal central apnea.” Epilepsia (2025). PMID: 40971258 ↗
L5OTHERCited in: Differential Diagnosis - [129]
Kochi R, Su TY, Punia V et al.. “Utility of MR fingerprinting in differentiating epileptogenic from non-epileptogenic cortical malformations.” Journal of the neurological sciences (2025). PMID: 40829437 ↗
L5OTHERCited in: Differential Diagnosis - [130]
Licchetta L, Mainieri G, Loddo G et al.. “Reliability and diagnostic accuracy of home video recording in differentiating sleep-related hypermotor epilepsy from disorders of arousal.” Epilepsia (2025). PMID: 40782112 ↗
L5OTHERCited in: Differential Diagnosis - [131]
Meletti S, Burani M, Ballerini A et al.. “Persistent Postictal Central Apnea in Focal Seizures: Incidence, Features, and Imaging Findings.” Neurology (2025). PMID: 40694793 ↗
L5OTHERCited in: Differential Diagnosis - [132]
Hu X, Li Z, Mo J et al.. “Differentiating Temporal Plus "Insula" Epilepsy From Temporal Lobe Epilepsy by Brain Networks Based on Noninvasive Examinations.” CNS neuroscience & therapeutics (2025). PMID: 40665829 ↗
L5OTHERCited in: Differential Diagnosis - [133]
Montenegro MA, Tsuha M, Sattar S. “Incidental interictal epileptiform discharges in infants with nonepileptic events.” Epilepsia (2025). PMID: 40394879 ↗
L5OTHERCited in: Differential Diagnosis - [134]
Dave H, McCreary M, Guerra A et al.. “Factors influencing seizure induction in patients with intracranial EEG recording.” Epilepsia (2025). PMID: 40019472 ↗
L5OTHERCited in: Differential Diagnosis - [135]
Ford J, Pevy N, Grunewald R et al.. “Can artificial intelligence diagnose seizures based on patients' descriptions? A study of GPT-4.” Epilepsia (2025). PMID: 40013839 ↗
L5OTHERCited in: Differential Diagnosis - [136]
Petropoulos IN, Aly KE, Al-Thani S et al.. “Corneal Confocal Microscopy Identifies and Differentiates Patients With Multiple Sclerosis and Epilepsy.” Translational vision science & technology (2024). PMID: 39671224 ↗
L5OTHERCited in: Differential Diagnosis - [137]
Morano A, Cerulli Irelli E, Fortunato F et al.. “Distinguishing seizures in autoimmune limbic encephalitis from mesial temporal lobe epilepsy with hippocampal sclerosis: Clues of a temporal plus network.” Journal of the neurological sciences (2024). PMID: 39546828 ↗
L5OTHERCited in: Differential Diagnosis - [138]
Sarthou A, Chrétien P, Giorgi L et al.. “The kappa free light chains index is an accurate diagnostic biomarker for paediatric multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2024). PMID: 39246003 ↗
L5OTHERCited in: Differential Diagnosis - [139]
Aaftink D, Reijneveld JC, de Lange F et al.. “Grading objective diagnostic components in paroxysmal events: One-year follow-up at a tertiary epilepsy center.” Epilepsia (2024). PMID: 39056373 ↗
L5OTHERCited in: Differential Diagnosis - [140]
Dobson H, Al Maawali S, Malpas C et al.. “Elevated plasma neurofilament light and glial fibrillary acidic protein in epilepsy versus nonepileptic seizures and nonepileptic disorders.” Epilepsia (2024). PMID: 39032019 ↗
L5OTHERCited in: Differential Diagnosis - [141]
Xiong W, Yeo T, May JTM et al.. “Distinct plasma metabolomic signatures differentiate autoimmune encephalitis from drug-resistant epilepsy.” Annals of clinical and translational neurology (2024). PMID: 39012808 ↗
L5OTHERCited in: Differential Diagnosis - [142]
Rider F, Turchinets A, Druzhkova T et al.. “Dissimilar Changes in Serum Cortisol after Epileptic and Psychogenic Non-Epileptic Seizures: A Promising Biomarker in the Differential Diagnosis of Paroxysmal Events?” International journal of molecular sciences (2024). PMID: 39000494 ↗
L5OTHERCited in: Differential Diagnosis - [143]
Saldaris JM, Demarest S, Jacoby P et al.. “Modification of a parent-report sleep scale for individuals with CDKL5 deficiency disorder: a psychometric study.” Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2024). PMID: 38963064 ↗
L5OTHERCited in: Differential Diagnosis - [144]
Maroufi SF, Fallahi MS, Amirkhani N et al.. “Laser interstitial thermal therapy versus open resective surgery for nontumoral epilepsy: systematic review and meta-analysis of comparative studies.” Journal of neurosurgery (2026). PMID: 41576371 ↗
L2aSR_OBSCited in: Surgical and Interventional Management - [145]
Estupiñan-Pepinosa DF, Correa-Molina N, Niño-Muñoz PA et al.. “Barriers to care in epilepsy surgery clinics in Latin America: a systematic review of social-economic impact.” Neurosurgical review (2026). PMID: 41504799 ↗
L2aSR_OBSCited in: Surgical and Interventional Management - [146]
Estupiñan-Pepinosa DF, Cordoba-Gallego MF, Quintero-Ruiz JP et al.. “Determinants of diagnostic accuracy and therapeutic outcomes of SEEG in epilepsy: a systematic review.” Neurosurgical review (2025). PMID: 41144046 ↗
L2aSR_OBSCited in: Surgical and Interventional Management - [147]
Rinella S, Lo Bianco M, Polizzi A et al.. “Efficacy of neurosurgical interventions for epilepsy in polymicrogyria: A systematic review.” Epilepsia open (2026). PMID: 41689720 ↗
L2aSR_OBSCited in: Surgical and Interventional Management - [148]
Jimenez AE, Feldstein NA, McKhann GM et al.. “Surgery for epilepsy secondary to vascular insults: A systematic review and meta-analysis of individual patient data.” Epilepsy research (2026). PMID: 41289957 ↗
L2aSR_OBSCited in: Surgical and Interventional Management - [149]
Puntambekar I, Koepp M, Xiao F et al.. “A systematic survey of the measures used to identify postoperative changes in language function following epilepsy surgery.” Epilepsia open (2025). PMID: 41118271 ↗
L2aSR_OBSCited in: Surgical and Interventional Management - [150]
Abbas A, Sabet H, El Refaei K et al.. “Robot-assisted versus frame-based stereoelectroencephalography (sEEG) electrode implantation in drug-resistant epilepsy: a meta-analysis of accuracy, efficiency, and safety.” Acta neurochirurgica (2026). PMID: 41721878 ↗
L2aSR_OBSCited in: Surgical and Interventional Management - [151]
Dickey AS, Reddy V, Rashied AA et al.. “Bayesian Estimation Improves Prediction of Outcomes After Epilepsy Surgery.” Annals of clinical and translational neurology (2026). PMID: 41413724 ↗
L2aSR_OBSCited in: Surgical and Interventional Management - [152]
Sideropoulou V, Patrikelis P, Messinis L et al.. “Executive Functioning Following Mesial Temporal Lobe Resective Surgery: A Systematic Review.” Advances in experimental medicine and biology (2026). PMID: 41273546 ↗
L2aSR_OBSCited in: Surgical and Interventional Management - [153]
Blihar D, Assi J, Breininger L et al.. “Callosotomy Outcomes: A Meta-Analysis.” World neurosurgery (2026). PMID: 41192505 ↗
L2aSR_OBSCited in: Surgical and Interventional Management - [154]
Grubor I, Strandberg MC, Bengzon J. “Nationwide registry-linked retrospective cohort study of Ganglioglioma in children and adults: Long-term follow-up of anti-seizure medication and mortality.” Seizure (2026). PMID: 41518691 ↗
L2bCOHORTCited in: Surgical and Interventional Management - [155]
Leocata A, di Giacomo R, Nazzi V et al.. “Temporal lobe disconnection in drug-resistant epilepsy associated with hippocampal sclerosis: how I do it.” Acta neurochirurgica (2026). PMID: 41792333 ↗
L4CASE_REPORTCited in: Surgical and Interventional Management - [156]
de Monaco BA, Santos AN, Cordeiro JG et al.. “Pulvinar responsive neurostimulation for posterior quadrant epilepsy: an illustrative case with connectome projection.” Neurosurgical review (2025). PMID: 41354955 ↗
L4CASE_REPORTCited in: Surgical and Interventional Management - [157]
El Khou Y, van Lanen RHGJ, Wagner GL et al.. “Pseudoaneurysms as a complication of stereoelectroencephalography: Case series and clinical recommendations.” Epilepsia (2026). PMID: 41347674 ↗
L4CASE_REPORTCited in: Surgical and Interventional Management - [158]
San-Juan D, Diaz-Peregrino R, Arellano-Reynoso A et al.. “A pilot comparative study of intraoperative results and surgical outcomes between asleep-awake-asleep and general anesthesia modalities in temporal lobe resections.” Neurosurgical review (2026). PMID: 41639492 ↗
L5OTHERCited in: Surgical and Interventional Management - [159]
Jaffee S, Onyekweli O, Mallela A et al.. “Association of electrocorticography and seizure outcomes in resective pediatric epilepsy surgery.” Journal of neurosurgery. Pediatrics (2026). PMID: 41616320 ↗
L5OTHERCited in: Surgical and Interventional Management - [160]
Wu Y, Zhang Z, Liang P et al.. “Outcomes of Predrug Resistant Versus Postdrug Resistant Surgery in Children With Focal Cortical Dysplasia-Related Epilepsy: Drug Resistance Should Not Be the Threshold for Surgical Candidacy.” Pediatric neurology (2026). PMID: 41570603 ↗
L5OTHERCited in: Surgical and Interventional Management - [161]
Pavlov V, Karazapryanov P, Gabrovski K et al.. “Avascular stereoelectroencephalography planning: comparison between MRA and T1-weighted MRI with double contrast.” Journal of neurosurgery (2026). PMID: 41569747 ↗
L5OTHERCited in: Surgical and Interventional Management - [162]
Nistal D, Buckley R, Boop S et al.. “Hemispherectomy in infants: an institutional experience with 21 patients.” Journal of neurosurgery. Pediatrics (2026). PMID: 41569724 ↗
L5OTHERCited in: Surgical and Interventional Management - [163]
Moore J, Jean J, Hanson J et al.. “Race, socioeconomic status, and geography influence utilization of surgery in Minnesota epilepsy patients.” Journal of neurosurgery (2026). PMID: 41569707 ↗
L5OTHERCited in: Surgical and Interventional Management - [164]
Peters PA, Zhou R, Singh R et al.. “Four-lead deep brain stimulation for multifocal drug-resistant epilepsy: surgical safety profile and preliminary effectiveness.” Journal of neurosurgery (2026). PMID: 41569668 ↗
L5OTHERCited in: Surgical and Interventional Management - [165]
Yardi R, Englot DJ, Wu C et al.. “Emerging technologies and strategies in epilepsy surgery: toward personalised medicine.” The Lancet. Neurology (2026). PMID: 41389832 ↗
L5REVIEW_NARRATIVECited in: Surgical and Interventional Management - [166]
Ortman C, Coorg R, Ali I et al.. “Clinical outcomes following stereotactic MRI-guided laser ablation in children with tuberous sclerosis complex and intractable epilepsy.” Epilepsia (2026). PMID: 41367165 ↗
L5OTHERCited in: Surgical and Interventional Management - [167]
Safa A, Ivaniuk A, Gauthier PJ et al.. “Intraoperative electrocorticography in awake brain surgery: comparing three electrode configurations for detecting stimulus-induced and spontaneous epileptiform activity.” Journal of neurosurgery (2026). PMID: 41349030 ↗
L5OTHERCited in: Surgical and Interventional Management - [168]
Aboubakr O, Mathon B. “How I do it: sequential robot-assisted stereotactic biopsy and laser interstitial thermal therapy for epilepsy associated with brain tumors.” Acta neurochirurgica (2025). PMID: 41339600 ↗
L5OTHERCited in: Surgical and Interventional Management - [169]
Rabiul Islam M, Bulacio JC, Bingaman W et al.. “Dynamic Stereoelectroencephalography-Based Phase-Amplitude Coupling in Cingulate Epilepsy.” International journal of neural systems (2026). PMID: 41299200 ↗
L5OTHERCited in: Surgical and Interventional Management - [170]
Giampiccolo D, van Dijk J, Granados A et al.. “Mapping white matter tracts with SEEG electrodes.” Epilepsia (2026). PMID: 41295969 ↗
L5OTHERCited in: Surgical and Interventional Management - [171]
Straub L, Hernandez-Diaz S, Bateman BT et al.. “Prenatal antiseizure drug exposure and risk of neurodevelopmental disorders in children: population based cohort study.” BMJ (Clinical research ed.) (2026). PMID: 41813017 ↗
L2bCOHORTCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [172]
Laux L, Sullivan J, Perry MS et al.. “Zorevunersen in Children and Adolescents with Dravet Syndrome.” The New England journal of medicine (2026). PMID: 41780062 ↗
L2bTRIAL_NONRANDOMCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics, Landmark Trials and Key Evidence - [173]
Kart PO, Serdaroglu E, Yildiz N et al.. “The efficacy and tolerability of lacosamide adjunctive therapy in children with drug-refractory epilepsy: A nationwide Turkish cohort study.” Epilepsy & behavior : E&B (2026). PMID: 41875756 ↗
L2bCOHORTCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [174]
Starck C, Helminen M, Nevalainen OP et al.. “Mortality and cause of death in childhood onset epilepsy: A population-based cohort study in Finland.” Seizure (2026). PMID: 41833258 ↗
L2bCOHORTCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [175]
Birbal S, Oosthuizen F, Naidoo U. “Evaluation of the management of high-risk obstetric patients living with epilepsy: A retrospective study from KwaZulu-Natal, South Africa.” South African family practice : official journal of the South African Academy of Family Practice/Primary Care (2026). PMID: 41773407 ↗
L2bCOHORTCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [176]
Serratosa JM, Gil-Nagel A, Toledo M et al.. “Seizure-free days as a clinical outcome measure of reduced epilepsy burden: 5-year outcomes with cenobamate treatment.” Epilepsy & behavior : E&B (2026). PMID: 41812435 ↗
L1bRCTCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [177]
Luo J, Wang T, Yan H et al.. “Clinical characterization of SPTBN1, SPTBN2, and SPTBN5 variants: A case series and systematic review.” Seizure (2026). PMID: 41819009 ↗
L2aSR_OBSCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [178]
Du R, Cao W, Sheng F et al.. “Impact of pediatric epilepsy on sleep architecture: A systematic review and meta-analysis.” Epilepsy research (2026). PMID: 41762486 ↗
L2aSR_OBSCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [179]
Ni G, Meng D. “Validity of screening tools and risk factors for Co-occurring ADHD in children with epilepsy: a systematic review and meta-analysis.” Epilepsy & behavior : E&B (2026). PMID: 41740565 ↗
L2aSR_OBSCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [180]
Herion I, Steinbart D, Dimova D et al.. “Postictal aggression in epilepsy: prevalence, clinical correlates, and psychosocial impact.” Journal of neurology (2026). PMID: 41946837 ↗
L5OTHERCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [181]
Liu P, Zhang L, Zeng Q et al.. “Efficacy and Safety of Zonisamide Addition in Children With Developmental Epileptic Encephalopathy/Epileptic Encephalopathy: A Real-World Study.” CNS neuroscience & therapeutics (2026). PMID: 41934115 ↗
L5OTHERCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [182]
Zhang N, Li S, Wang T et al.. “The role of China's acute seizure action plan in the management of out-of-hospital seizures in children with epilepsy: a pilot study.” Frontiers in public health (2026). PMID: 41919287 ↗
L5OTHERCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [183]
De Pace R, Dominguez Gonzalez CA, Williamson CD et al.. “BLOC1S1 variants cause lysosomal and autophagic defects resulting in a hypomyelinating leukodystrophy with epileptic encephalopathy.” American journal of human genetics (2026). PMID: 41887224 ↗
L5OTHERCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [184]
Lee ST, Patel S, Karakas C et al.. “Responsive neurostimulation in children, adolescents, and young Adults-Longitudinal effectiveness and safety.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2026). PMID: 41863185 ↗
L5OTHERCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [185]
Brinyark HE, Chatfield R, Coyne CA et al.. “Optimization of cortico-cortical spectral response analysis parameters for seizure onset zone localization.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 41861446 ↗
L5OTHERCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [186]
Bozkaya-Yilmaz S, Dagdas SM, Firat E et al.. “Investigation of adolescent cases diagnosed with idiopathic/genetic generalized epilepsy in terms of self-esteem, aggression, body perception, and alexithymia.” European journal of pediatrics (2026). PMID: 41857384 ↗
L5OTHERCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [187]
Yin J, He Z, Lu L et al.. “Bidirectional associations between functional gastrointestinal disorders and epilepsy and the mediating role of mental health: A population-based study.” Journal of affective disorders (2026). PMID: 41825748 ↗
L5OTHERCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [188]
Tailby C, Chapman J, Helmstaedter C et al.. “Telehealth enabled neuropsychological testing (TENT): a new platform for examiner-led, digital cognitive assessment.” Journal of neurology (2026). PMID: 41803496 ↗
L5OTHERCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [189]
Zhao J, Chen Q, Dong J et al.. “Global, regional, and national burden of epilepsy, 1990-2021: a Global Burden of Disease study.” Journal of global health (2026). PMID: 41789520 ↗
L5OTHERCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [190]
Coleman SC, Suresh H, Mithani K et al.. “Association of Brain Network Perturbations With Response to Vagus Nerve Stimulation in Children With Drug-Resistant Focal Epilepsy.” Neurology (2026). PMID: 41771009 ↗
L5OTHERCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [191]
Millogo A, Dermauw V, Ganaba R et al.. “Prevalence of neurocysticercosis and its characteristics among people with epileptic seizures and progressively worsening severe headaches in 60 villages in three provinces of Burkina Faso.” PLoS neglected tropical diseases (2026). PMID: 41746951 ↗
L5OTHERCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [192]
Zehtabchi S, Beall J, Silbergleit R et al.. “Chronological Sequence of Convulsive Status Epilepticus Treatment Steps in a Real-Life Scenario for Patients Enrolled in a Large Multicenter Trial.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 41854499 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [193]
Jenkinson MD, Bulbeck H, Carruthers J et al.. “Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT.” Health technology assessment (Winchester, England) (2026). PMID: 41797548 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [194]
Koepp MJ, Trinka E, Mah YH et al.. “Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post-stroke epilepsy: a proof-of-concept, phase 2a, randomised, double-blind, placebo-controlled antiepileptogenesis trial.” The Lancet. Neurology (2026). PMID: 41722592 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [195]
Modi AC, Wagner JL, Patel AD et al.. “mHealth adherence in pediatric epilepsy: Outcomes of a sequential, multiple assignment, randomized trial (SMART).” Epilepsia (2026). PMID: 41579063 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [196]
Al-Fatuhi-Al-Jundi Z, Avenas S, Tankéré P et al.. “Dynamics of early electroencephalographic patterns and epileptic seizures in acute intracerebral hemorrhage: A prospective controlled study.” Epilepsia (2026). PMID: 41250972 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [197]
Kawai K, Choe E, Ferrari L et al.. “Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double-blind, placebo-controlled study in a multinational Asian population.” Epilepsia (2026). PMID: 41230998 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [198]
Robinson JD, Anthenelli RM, Cinciripini PM et al.. “High- and low-dose topiramate for the treatment of persons with alcohol use disorder who smoke cigarettes: A randomized control trial.” Alcohol, clinical & experimental research (2025). PMID: 41220371 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [199]
French J, Bosak M, Kerr WT et al.. “A randomized, double-blind, placebo-controlled, time-to-event study of the efficacy and safety of JNJ-40411813 in combination with levetiracetam or brivaracetam in patients with focal onset seizures.” Epilepsia (2026). PMID: 41175011 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [200]
Lee SK, Yu P, Choe E et al.. “A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures.” Epilepsia (2026). PMID: 41144696 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [201]
Dlugos DJ, Scheffer IE, French JA et al.. “Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC).” Epilepsia (2026). PMID: 41133912 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [202]
O'Kelley SE, Capal JK, McPherson TO et al.. “Neurodevelopmental Outcomes From the PREVeNT Trial.” Pediatric neurology (2025). PMID: 41061327 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [203]
Wu X, Chen L, Choe E et al.. “Efficacy of adjunctive cenobamate by focal seizure subtypes: a randomized, double-blind, placebo-controlled, multicenter study in a multinational Asian population.” Seizure (2025). PMID: 41101116 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [204]
Klein P, Aungaroon G, Biton V et al.. “Pharmacokinetics and tolerability of single-dose Staccato® alprazolam in adolescents with epilepsy, and population pharmacokinetic analysis to support dose selection in adolescents.” Epilepsia (2026). PMID: 41133403 ↗
L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence - [205]
Ardekani A, Sanchez-Rodriguez A, Gonzalez-Treviño M et al.. “Risk factors and outcomes of posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a retrospective-multicentre cohort study and systematic literature review.” Lupus science & medicine (2025). PMID: 41381247 ↗
L2aSR_OBSCited in: Landmark Trials and Key Evidence - [206]
Gringras P, Anilkumar A, Bray L et al.. “Randomised controlled trial of online behavioural sleep intervention for children with epilepsy.” Scientific reports (2026). PMID: 41501108 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [207]
Jiang P, Jiang Z, Sui H et al.. “Impact of Collateral Circulation on Poststroke Epilepsy After Mechanical Thrombectomy for Large Vessel Occlusive Stroke: A Multicenter Cohort Study.” European journal of neurology (2025). PMID: 41270220 ↗
L2bCOHORTCited in: Landmark Trials and Key Evidence - [208]
Wei Z, Liu T, Cao D et al.. “Resective Surgery for Drug-Resistant Epilepsy in Patients With Tuberous Sclerosis Complex: A Prospective Nationwide Multicenter Cohort Study.” Neurology (2025). PMID: 41100778 ↗
L2bCOHORTCited in: Landmark Trials and Key Evidence - [209]
Mastrangelo M, Tolve M, Valenzuela I et al.. “Epilepsy phenotypes of Renu syndrome: Novel insights from a European multicentre retrospective cohort study.” Seizure (2026). PMID: 41570780 ↗
L2bCOHORTCited in: Landmark Trials and Key Evidence - [210]
Sadeghzadeh S, Purger DA, Bhanot P et al.. “sEEG-guided responsive neurostimulation to treat neocortical epilepsy: A multicenter retrospective study of the efficacy and safety of depth electrode-mediated neuromodulation.” Epilepsia open (2026). PMID: 41251192 ↗
L2bCOHORTCited in: Landmark Trials and Key Evidence - [211]
Barnard SN, French JA, Chen Z et al.. “Suicidality at Epilepsy Diagnosis and Future Treatment Resistance in Adults With Focal Epilepsy.” JAMA neurology (2026). PMID: 41801192 ↗
L5OTHERCited in: Landmark Trials and Key Evidence - [212]
Bai L, Lin N, Zhang X et al.. “Prognostic factors and a preliminary prognostic model in anti-GAD antibody-associated epilepsy.” Frontiers in immunology (2026). PMID: 41716410 ↗
L5OTHERCited in: Landmark Trials and Key Evidence - [213]
Cao V, Chiu MY, Chellamani H et al.. “Does First-Line Treatment Impact Outcomes in Trisomy 21-Associated Infantile Epileptic Spasms Syndrome? A Multicenter North American Analysis.” Pediatric neurology (2026). PMID: 41689988 ↗
L5OTHERCited in: Landmark Trials and Key Evidence - [214]
Cerulli Irelli E, Roberti R, Borioni MS et al.. “Comparative Effectiveness of Brivaracetam, Cenobamate, Lacosamide, and Perampanel in Focal Epilepsy.” JAMA neurology (2026). PMID: 41661607 ↗
L5OTHERCited in: Landmark Trials and Key Evidence - [215]
Pack AM, Oskoui M, Williams Roberson S et al.. “Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM.” Neurology (2024). PMID: 38748979 ↗
L1cGUIDELINECited in: Guidelines and Resources - [216]
Patsalos PN, Berry DJ, Bourgeois BF et al.. “Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.” Epilepsia (2008). PMID: 18397299 ↗
L1cGUIDELINECited in: Guidelines and Resources - [217]
Kanner AM, Ashman E, Gloss D et al.. “Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.” Neurology (2018). PMID: 29898971 ↗
L1cGUIDELINECited in: Guidelines and Resources - [218]
Peltola ME, Leitinger M, Halford JJ et al.. “Routine and sleep EEG: Minimum recording standards of the International Federation of Clinical Neurophysiology and the International League Against Epilepsy.” Epilepsia (2023). PMID: 36762397 ↗
L1cGUIDELINECited in: Guidelines and Resources - [219]
Gloss D, Pargeon K, Pack A et al.. “Antiseizure Medication Withdrawal in Seizure-Free Patients: Practice Advisory Update Summary: Report of the AAN Guideline Subcommittee.” Neurology (2021). PMID: 34873018 ↗
L1cGUIDELINECited in: Guidelines and Resources - [220]
Walbert T, Harrison RA, Schiff D et al.. “SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.” Neuro-oncology (2021). PMID: 34174071 ↗
L1cGUIDELINECited in: Guidelines and Resources - [221]
Gaillard WD, Chiron C, Cross JH et al.. “Guidelines for imaging infants and children with recent-onset epilepsy.” Epilepsia (2009). PMID: 19389145 ↗
L1cGUIDELINECited in: Guidelines and Resources - [222]
Compagno Strandberg M, Söderberg-Löfdal K, Kimland E et al.. “Evidence-based anti-seizure monotherapy in newly diagnosed epilepsy: A new approach.” Acta neurologica Scandinavica (2020). PMID: 32627842 ↗
L1cGUIDELINECited in: Guidelines and Resources - [223]
Cross JH, Jayakar P, Nordli D et al.. “Proposed criteria for referral and evaluation of children for epilepsy surgery: recommendations of the Subcommission for Pediatric Epilepsy Surgery.” Epilepsia (2006). PMID: 16822241 ↗
L1cGUIDELINECited in: Guidelines and Resources - [224]
Rosenow F, Alonso-Vanegas MA, Baumgartner C et al.. “Cavernoma-related epilepsy: review and recommendations for management--report of the Surgical Task Force of the ILAE Commission on Therapeutic Strategies.” Epilepsia (2013). PMID: 24134485 ↗
L1cGUIDELINECited in: Guidelines and Resources - [225]
Cortese S, Holtmann M, Banaschewski T et al.. “Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.” Journal of child psychology and psychiatry, and allied disciplines (2013). PMID: 23294014 ↗
L1cGUIDELINECited in: Guidelines and Resources - [226]
Tolchin B, Goldstein LH, Reuber M et al.. “Management of Functional Seizures Practice Guideline Executive Summary: Report of the AAN Guidelines Subcommittee.” Neurology (2026). PMID: 41370742 ↗
L1cGUIDELINECited in: Guidelines and Resources - [227]
Beniczky S, Wiebe S, Jeppesen J et al.. “Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2021). PMID: 33678577 ↗
L1cGUIDELINECited in: Guidelines and Resources - [228]
Beniczky S, Wiebe S, Jeppesen J et al.. “Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology.” Epilepsia (2021). PMID: 33666944 ↗
L1cGUIDELINECited in: Guidelines and Resources - [229]
Appleton RE, Freeman A, Cross JH. “Diagnosis and management of the epilepsies in children: a summary of the partial update of the 2012 NICE epilepsy guideline.” Archives of disease in childhood (2012). PMID: 23042803 ↗
L1cGUIDELINECited in: Guidelines and Resources - [230]
Glauser T, Ben-Menachem E, Bourgeois B et al.. “ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.” Epilepsia (2006). PMID: 16886973 ↗
L1cGUIDELINECited in: Guidelines and Resources - [231]
Harden CL, Pennell PB, Koppel BS et al.. “Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society.” Epilepsia (2009). PMID: 19507305 ↗
L1cGUIDELINECited in: Guidelines and Resources - [232]
Harden CL, Hopp J, Ting TY et al.. “Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society.” Epilepsia (2009). PMID: 19496807 ↗
L1cGUIDELINECited in: Guidelines and Resources - [233]
Harden CL, Meador KJ, Pennell PB et al.. “Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society.” Epilepsia (2009). PMID: 19507301 ↗
L1cGUIDELINECited in: Guidelines and Resources - [234]
Beniczky S, Trinka E, Wirrell E et al.. “A practical guide to the updated seizure classification 2025.” Epileptic disorders : international epilepsy journal with videotape (2025). PMID: 41081650 ↗
L1cGUIDELINECited in: Guidelines and Resources - [235]
Sánchez-Álvarez JC, Mauri-Llerda JA, Gil-Nagel A et al.. “Consensus-recommended diagnostic and therapeutic guidelines for drug-resistant epilepsy in Spain (Consenso RATE-España).” Neurologia (Barcelona, Spain) (2012). PMID: 22078652 ↗
L1cGUIDELINECited in: Guidelines and Resources - [236]
Sánchez-Álvarez JC, Gil-Nagel A, Casas-Fernández C et al.. “Drug-resistant epilepsy: current recommendations for diagnosis and treatment in Spain.” Neurologia (Barcelona, Spain) (2012). PMID: 22078651 ↗
L1cGUIDELINECited in: Guidelines and Resources - [237]
Koutroumanidis M, Arzimanoglou A, Caraballo R et al.. “The role of EEG in the diagnosis and classification of the epilepsy syndromes: a tool for clinical practice by the ILAE Neurophysiology Task Force (Part 2).” Epileptic disorders : international epilepsy journal with videotape (2017). PMID: 29350182 ↗
L1cGUIDELINECited in: Guidelines and Resources - [238]
Kellinghaus C, Loddenkemper T, Wyllie E et al.. “[Suggestion for a new, patient-oriented epilepsy classification].” Der Nervenarzt (2006). PMID: 16821062 ↗
L1cGUIDELINECited in: Guidelines and Resources - [239]
Blümcke I, Mühlebner A. “Neuropathological work-up of focal cortical dysplasias using the new ILAE consensus classification system - practical guideline article invited by the Euro-CNS Research Committee.” Clinical neuropathology (2011). PMID: 21726501 ↗
L1cGUIDELINECited in: Guidelines and Resources - [240]
Ekstein D, Noyman I, Fahoum F et al.. “Treating Epilepsy Patients with Investigational Anti-COVID-19 Drugs: Recommendations by the Israeli Chapter of the ILAE.” The Israel Medical Association journal : IMAJ (2020). PMID: 33249784 ↗
L1cGUIDELINECited in: Guidelines and Resources - [241]
Riccardi F, Desnous B, Borloz E et al.. “Burst-Suppression EEG in Early Infantile Developmental and Epileptic Encephalopathies: Phenotype, Genotype, and Outcome.” Neurology (2026). PMID: 42190144 ↗
L4Cited in: Pathophysiology - [242]
Long Z, Gong S, Ji D et al.. “CACNA1A c.5610del in a three-generation family: epilepsy with ataxia/migraine.” BMC neurology (2026). PMID: 42067833 ↗
L3bCited in: Pathophysiology - [243]
Günay Ç, Yılmazbilek İ, Soydemir D et al.. “The role of DHH motifs in PRUNE1 gene on ion channels: A new insight into epilepsy pathogenesis.” Epilepsy research (2026). PMID: 41980489 ↗
L3bCited in: Pathophysiology - [244]
Dell'Isola GB, Muda A, Giordano L et al.. “Fenfluramine in SCN1A-related GEFS+: A multicenter observational study on efficacy, EEG improvement, and tolerability.” Epilepsia open (2026). PMID: 41739881 ↗
L4Cited in: Pathophysiology - [245]
Li R, Wang C, Geng R et al.. “Clinical and genetic analysis of epilepsy in children with SCN8A gene variants.” Seizure (2025). PMID: 41380541 ↗
L4Cited in: Pathophysiology - [246]
Muthaffar O, Alsubhan M, Mir A et al.. “Clinical and Genetic Spectrum of SCN8A-Related Disorders: A Retrospective Study From the Gulf Region.” Journal of child neurology (2025). PMID: 41325016 ↗
L3bCited in: Pathophysiology - [247]
Samanta D. “SLC6A1-Related Neurodevelopmental Disorder: A Scoping Review of Clinical Features and Emerging Therapeutic Strategies.” Pediatric neurology (2026). PMID: 42173049 ↗
L5Cited in: Pathophysiology - [248]
Pelorosso C, Balestrini S, Guerrini R. “Potassium channel agonists emerging as treatment options for focal epilepsy: are we breaking new ground?” Expert opinion on emerging drugs (2026). PMID: 42153277 ↗
L5Cited in: Pathophysiology - [249]
Nelson AT, Hill SF, Simon M et al.. “In vivo adenine base editing ameliorates Dravet syndrome phenotypes in a mouse model.” Science translational medicine (2026). PMID: 42127220 ↗
L5Cited in: Pathophysiology - [250]
Kissling L, Pietrafesa F, Ranucci M et al.. “Prime editing of a pathogenic Scn1a allele ameliorates seizure phenotypes in a GEFS+ mouse model.” Science translational medicine (2026). PMID: 42127217 ↗
L5Cited in: Pathophysiology - [251]
Ma A, Gong P, Jiao X et al.. “KCNA2 Variants in Epilepsy: Focusing on Spike-and-Wave Activation in Sleep.” Pediatric neurology (2026). PMID: 42033987 ↗
L5Cited in: Pathophysiology - [252]
Abdelaziz AM, Fawzy MN, Fathy MK et al.. “From insult to hyperexcitability: pharmacological targeting of MyD88 and JAK/STAT3 pathways in epilepsy.” Inflammopharmacology (2026). PMID: 41974982 ↗
L5Cited in: Pathophysiology - [253]
Löscher W, White HS, Klein P. “The Complexity and Challenges of Developing Effective Epilepsy Therapies: Lessons to be Learned from Comparing Cenobamate, Carisbamate, and Padsevonil.” CNS drugs (2026). PMID: 41915362 ↗
L5Cited in: Pathophysiology - [254]
Genin A, Janvier A, Moujellil-Legagneur T et al.. “Long-lasting remodeling of astrocytes in an Scna1+/- mouse model of Dravet syndrome.” Epilepsia (2026). PMID: 41841337 ↗
L5Cited in: Pathophysiology - [255]
Pan H, Liu D, Xu W et al.. “KCNJ4 variants disrupt inward-rectifier potassium channel function and cause refractory epilepsy.” Epilepsia (2026). PMID: 41830586 ↗
L5Cited in: Pathophysiology - [256]
Tan M, Goad BS, Allen M et al.. “Mechanisms of SCN2A loss of function do not predict presence or phenotype of epilepsy.” Epilepsia (2026). PMID: 41642117 ↗
L5Cited in: Pathophysiology - [257]
Durmus I, Sezen O, Cevik B et al.. “Comparison of the Effects of Dexmedetomidine and Remifentanil on Seizure Duration, Hemodynamics, and Recovery Time in Electroconvulsive Therapy.” The journal of ECT (2026). PMID: 40424541 ↗
L1bCited in: History and Physical Examination - [258]
Hu W, Liu TS, Tian G et al.. “Associations and Potential Biological Pathways Between Physical Frailty and Epilepsy Incidence: A Large-Scale Prospective Cohort Study.” Neurology (2026). PMID: 42133910 ↗
L2bCited in: History and Physical Examination - [259]
Schwarzer J, Khadhraoui E, Einspänner E et al.. “Local brain volume reductions in patients with non-lesional epilepsy on 7T MRI.” Neuroradiology (2025). PMID: 41251771 ↗
L4Cited in: History and Physical Examination - [260]
Carvalho RL, Borges DF, Casalta-Lopes J et al.. “Hippocampal volume loss in mesial temporal lobe epilepsy: Magnitude and laterality in a meta-analysis of MRI volumetry studies.” Epilepsy & behavior : E&B (2026). PMID: 41962380 ↗
L2aCited in: History and Physical Examination - [261]
Ujihara M, Kawabori M, Nakajima M et al.. “Thalamic Volume Asymmetry as a Potential Predictor of Vagus Nerve Stimulation Outcomes in Refractory Epilepsy.” Neurologia medico-chirurgica (2026). PMID: 42203441 ↗
L4Cited in: History and Physical Examination - [262]
Wang J, He Z, Shen S et al.. “Genetic risk, antiseizure medications, and lifestyle factors in epilepsy-associated obesity and overweight.” International journal of obesity (2005) (2026). PMID: 41942740 ↗
L3bCited in: History and Physical Examination - [263]
Bozdag E, Makaram N, Sabino G et al.. “Interictal cardiac repolarization abnormalities improve after surgical seizure resolution in pediatric drug-resistant epilepsy.” Epilepsia (2026). PMID: 41848583 ↗
L3bCited in: History and Physical Examination - [264]
Kubur ÇÇ, Özyurt BC, Alkan F et al.. “Electrocardiographic repolarization and conduction abnormalities in pediatric epilepsy.” Epilepsy & behavior : E&B (2026). PMID: 41825277 ↗
L2bCited in: History and Physical Examination - [265]
Dereli AS, Apaire A, Germany Morrison E et al.. “Seizure-type-specific disruption of hypercapnic cardioventilatory responses in epilepsy models.” Epilepsia (2026). PMID: 41701016 ↗
L3bCited in: History and Physical Examination - [266]
Calcaterra V, Labati L, Scavone IAM et al.. “Thyroid-metabolic interactions in pediatric epilepsy: insights from central sensitivity indices and peripheral hormone markers.” European journal of pediatrics (2026). PMID: 42104025 ↗
L3bCited in: History and Physical Examination - [267]
Andersson K, Boxum M, Srikrishna M et al.. “Gray matter volume associations with clinical outcomes in epilepsy: A regional cohort study.” Epilepsy research (2026). PMID: 41864089 ↗
L3bCited in: History and Physical Examination - [268]
Eliashiv D, Rao VR, Jobst BC et al.. “Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy: Three-Year Efficacy and Interim Safety Results.” Neurology (2026). PMID: 42030518 ↗
L1bCited in: Clinical Features and Seizure Variants - [269]
Martinelli R, Ciaffi G, Fuggetta F et al.. “Prognostic factors in vagus nerve stimulation for drug-resistant epilepsy. Results from a systematic review and meta-analysis of the literature.” Neurosurgical review (2026). PMID: 42307795 ↗
L2aCited in: Clinical Features and Seizure Variants - [270]
Lin J, Ji Z, Wu L et al.. “Epileptiform patterns in electroencephalography and clinical myoclonic seizures predict unfavorable outcomes in patients after cardiac arrest: a meta-analysis protocol.” Systematic reviews (2026). PMID: 41872966 ↗
L2aCited in: Clinical Features and Seizure Variants - [271]
Barnagian D, In E, Xiong Y et al.. “Surgical Interventions for Super-Refractory Status Epilepticus: A Systematic Review.” Neurocritical care (2026). PMID: 41817835 ↗
L4Cited in: Clinical Features and Seizure Variants - [272]
Pavan S, Mazzon G, Furlanis G et al.. “Ketamine in super-refractory status epilepticus: Combined value of inflammatory biomarkers and EEG features.” Epilepsia (2026). PMID: 41973529 ↗
L4Cited in: Clinical Features and Seizure Variants - [273]
Morcos S, Falbo K, Seltzer L et al.. “Natural History of YWHAG-Associated Neurodevelopmental Disorder.” Pediatric neurology (2026). PMID: 41886798 ↗
L2bCited in: Clinical Features and Seizure Variants - [274]
Le Z, Ou Z, Yan R et al.. “Efficacy and safety of novel antiseizure medications as adjunctive treatment of focal epilepsy: An updated network meta-analysis.” Seizure (2026). PMID: 42054833 ↗
L2aCited in: Clinical Features and Seizure Variants - [275]
Bolle AE, Sarria-Estrada S, Bonduelle T et al.. “Peri-ictal magnetic resonance imaging abnormalities during status epilepticus in adults with idiopathic generalized epilepsy.” Epilepsy & behavior : E&B (2026). PMID: 42000483 ↗
L2aCited in: Clinical Features and Seizure Variants - [276]
Nathan CL, Ghandour D, Cunningham EM et al.. “Epilepsy characteristics and outcomes in patients with pleomorphic xanthoastrocytomas.” Journal of neuro-oncology (2026). PMID: 42319547 ↗
L3bCited in: Clinical Features and Seizure Variants - [277]
Bader ER, Kemball-Cook WS, Benton JA et al.. “Rural-Urban Disparities in Epilepsy Outcomes in the United States.” Neurology (2026). PMID: 42234954 ↗
L3bCited in: Clinical Features and Seizure Variants - [278]
Chen H, Zhong J, Chen Y et al.. “Clinical application of HMGB1-TLR4 signaling pathway-mediated neuroinflammatory markers in infantile epileptic spasms syndrome.” Frontiers in immunology (2026). PMID: 42148092 ↗
L3bCited in: Clinical Features and Seizure Variants - [279]
Cantarín-Extremera V, Ballarà-Petitbò M, Jiménez-Legido M et al.. “Clinical spectrum, diagnosis, cognitive outcomes and therapeutic strategies in pediatric Rasmussen syndrome: a 10-year cohort from a tertiary pediatric center.” Orphanet journal of rare diseases (2026). PMID: 42057109 ↗
L4Cited in: Clinical Features and Seizure Variants - [280]
Jonker R, Schieving J. “Epilepsy in pediatric patients with PTEN hamartoma tumor syndrome: First step in recommendations for clinical management.” European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society (2026). PMID: 41825102 ↗
L3bCited in: Clinical Features and Seizure Variants - [281]
Swinnen L, Bhagubai M, Chatzichristos C et al.. “A multicenter, video-EEG-based validation of a multimodal wearable device for focal seizure detection in adults: The SeizeIT2 study.” Epilepsia open (2026). PMID: 41949013 ↗
L2bCited in: Clinical Features and Seizure Variants - [282]
Meletti S, Hanin A, Giovannini G et al.. “Acute Brain Injury in New-Onset Refractory Status Epilepticus and Etiology-Defined Status Epilepticus.” JAMA neurology (2026). PMID: 42043830 ↗
L3bCited in: Clinical Features and Seizure Variants - [283]
Zhao HQ, Li XZ, Ma Y et al.. “UNC13A-related neurodevelopmental disorders in children: epilepsy phenotypes and antiseizure medication response.” Seizure (2026). PMID: 42385283 ↗
L4Cited in: Clinical Features and Seizure Variants - [284]
Balestrini S, Puliti D, Lombardini M et al.. “Efficacy of Levetiracetam in Patients With Pediatric Epilepsy: A Systematic Review and Meta-Analysis.” Neurology (2026). PMID: 42202238 ↗
L1aCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [285]
de Oliveira HM, Oliveira Fonseca PE, Trejo Elías JE et al.. “Cannabidiol Use in Developmental and Epileptic Encephalopathies: A Syndrome- and Age-Stratified Systematic Review and Meta-analysis.” CNS drugs (2026). PMID: 42185726 ↗
L1aCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [286]
Saron H, Cook G, Wiggs L et al.. “'I Didn't Even Associate the Two Together at All': A Qualitative Study of 'Information Work' Undertaken by Parents and Their Children With Epilepsy to Make Sense of Sleep and Seizures.” Health expectations : an international journal of public participation in health care and health policy (2026). PMID: 42444506 ↗
L1bCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [287]
Guinchard M, Rossetti AO, Schindler K et al.. “Effects of midazolam and propofol on EEG detection of epileptiform activity in patients with altered consciousness.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 42202614 ↗
L1bCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [288]
Karacabey BN, Gökçeer D, Coşkun O et al.. “Cardiac effects of one-year levetiracetam monotherapy in children with genetic generalized epilepsy: a prospective longitudinal study.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42315704 ↗
L4Cited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [289]
Honybun E, Malpas CB, Graham JE et al.. “Neurocognitive Outcomes of In Utero Exposure to Antiseizure Medication: An Australian Cohort Study.” Neurology (2026). PMID: 42247656 ↗
L4Cited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [290]
Zeng Q, Xia X, Zheng H et al.. “Efficacy and Safety of Adjunctive Perampanel in Young Children (7-46 Months) With Drug-Resistant Epilepsy: A Real-World Study.” CNS neuroscience & therapeutics (2026). PMID: 42322072 ↗
L2bCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [291]
Coates R, Hudson M, Schröder T et al.. “What is the impact of stigma on the wellbeing of children with epilepsy?: A qualitative systematic literature review.” Seizure (2026). PMID: 42308772 ↗
L2aCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [292]
Altıntaş M, Yıldırım M, Kırık S et al.. “Genotypic and phenotypic heterogeneity in tubulinopathies: insights from a Turkish multicenter cohort.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42472988 ↗
L4Cited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [293]
Buonocore J, Fortunato F, Fratto E et al.. “Risk of epilepsy in people with adult-onset hydrocephalus: insights from the UK Biobank.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42458109 ↗
L3bCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [294]
Driollet B, Buajitti E, Ahmed AM et al.. “Association of severe maternal morbidity with epilepsy diagnosis in children: a population-based birth cohort study.” International journal of epidemiology (2026). PMID: 42435418 ↗
L3bCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [295]
Rollins S, Radosevich JJ, Sammani N et al.. “Rapid administration of undiluted IV push valproic acid.” Journal of neurology (2026). PMID: 42429979 ↗
L3bCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [296]
Millington E, Rydzewska E, Jahoda A et al.. “Temporal associations between incident physical health problems/sensory impairments and challenging behaviours in people with intellectual disabilities: a population-based longitudinal cohort study of primary care in England.” BMJ open (2026). PMID: 42398996 ↗
L3bCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [297]
Chen Z, Gliske SV, Alsammani A et al.. “The Influence of Recording Duration and Vigilance State on High-Frequency Oscillation Characterization in Epilepsy.” Neurology (2026). PMID: 42348802 ↗
L4Cited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [298]
Fashuang L, Mingbiao M, Na L et al.. “Prediction of Zonisamide Concentration in Pediatric Patients With Epilepsy: A Machine Learning Approach.” CNS neuroscience & therapeutics (2026). PMID: 42329187 ↗
L3bCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [299]
Peltz C, Albrecht J, Bahorik AL et al.. “Neurologic Diagnoses Before and After Traumatic Brain Injury: A Retrospective Cohort Study of Older Veterans.” Neurology (2026). PMID: 42308449 ↗
L3bCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [300]
Dörr N, Hüsing T, Kleespies H et al.. “Epilepsy in older adults: a comparison of early-onset persistent and late-onset epilepsy.” Journal of neurology (2026). PMID: 42265397 ↗
L3bCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [301]
Taximi S, Angeli M, Chranioti I et al.. “Cenobamate in pediatric drug-resistant epilepsy: real-world evidence from a two-center retrospective study.” European journal of pediatrics (2026). PMID: 42213138 ↗
L3bCited in: Special Populations: Pediatrics, Pregnancy, and Geriatrics - [302]
Winston GP, Salemme S, Cantalupo G et al.. “Recommendations for structural magnetic resonance imaging in infants with first afebrile seizure or new onset epilepsy: Evidence-based recommendations from the ILAE Neuroimaging Task Force.” Epilepsia (2026). PMID: 41894169 ↗
L1cCited in: Guidelines and Resources - [303]
Karaer D, Yüzbaşı BK, Şahin İ et al.. “Clinical utility and genetic landscape of exome sequencing in a large pediatric epilepsy cohort: Insights from a Turkish tertiary care center.” Epileptic disorders : international epilepsy journal with videotape (2026). PMID: 42394473 ↗
L4Cited in: Pathophysiology - [304]
Liebovitz LN, Thompson CH, Laux LC et al.. “Epilepsy-Associated Variants of a Single SCN1A Codon Exhibit Divergent Functional Properties.” Annals of clinical and translational neurology (2026). PMID: 41718449 ↗
L4Cited in: Pathophysiology - [305]
Scheffer IE, Perry MS, Sullivan J et al.. “Characterizing early behavioral and social-emotional problems in young children with SCN1A+ Dravet syndrome: Findings from the ENVISION prospective natural history study.” Epilepsia (2026). PMID: 41627953 ↗
L5Cited in: Pathophysiology - [306]
Perucca P, Malpas CB, Berry-Noronha A et al.. “Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study.” The Lancet. Neurology (2026). PMID: 42586099 ↗
L2bCited in: History and Physical Examination - [307]
Xu J, Geng J, Wang J et al.. “Heart rate variability in epilepsy and its association with disease duration: a retrospective case-control study.” Frontiers in neurology (2026). PMID: 42609212 ↗
L2bCited in: History and Physical Examination - [308]
Chabardès S, Bartolomei F, Nica A et al.. “Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial.” Epilepsia (2026). PMID: 41902639 ↗
L1bCited in: Landmark Trials and Key Evidence - [309]
Guerrini R, Marsh ED, Liao WP et al.. “A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox-Gastaut syndrome.” Epilepsia (2026). PMID: 41891667 ↗
L1bCited in: Landmark Trials and Key Evidence - [310]
Sullivan J, Valente K, Villanueva V et al.. “Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome.” Epilepsia (2026). PMID: 41784472 ↗
L1bCited in: Landmark Trials and Key Evidence - [311]
Karpychev V, Roth RW, Yun W et al.. “Prediction of Long-Term Postsurgical Seizure Recurrence From MRI Brain Hub Disruption in Patients With Temporal Lobe Epilepsy.” Neurology (2026). PMID: 42585607 ↗
L2bCited in: Landmark Trials and Key Evidence - [312]
Cheng Y, Li J, Yang Y. “Serum Uric Acid as a Sex-Dependent Risk Marker of Post-Stroke Epilepsy After Acute Ischemic Stroke: Complementary Mendelian Randomization and Cohort Analyses.” CNS neuroscience & therapeutics (2026). PMID: 42257821 ↗
L2bCited in: Landmark Trials and Key Evidence - [313]
Reitsma FJ, Verburgt E, Schellekens MMI et al.. “Poststroke epilepsy is associated with vascular cognitive disorder in young stroke patients: The ODYSSEY study.” Epilepsia (2026). PMID: 41830426 ↗
L2bCited in: Landmark Trials and Key Evidence - [314]
Glass HC, Numis AL, Soul JS et al.. “Long-term safety of early discontinuation of antiseizure medication after resolution of acute provoked neonatal seizures.” Epilepsia (2026). PMID: 41826797 ↗
L2bCited in: Landmark Trials and Key Evidence - [315]
Kerr WT, McFarlane KN, Ngo LY et al.. “Systematic statistical analysis of change in SEIzure interVAL with diazepam nasal spray supports this novel clinical endpoint for immediate-use seizure medication.” Epilepsia (2026). PMID: 41919765 ↗
L2bCited in: Landmark Trials and Key Evidence - [316]
Foster EC, Millist L, Germaine J et al.. “A first in disease trial of the safety, tolerability, and anti-seizure effects of ES-481 in drug-resistant epilepsy.” Epilepsia open (2026). PMID: 42312676 ↗
L2bCited in: Landmark Trials and Key Evidence - [317]
Viana PF, McWilliam M, Koren J et al.. “Monitoring Antiseizure Medication Change Using Ultra Long-Term Electroencephalogram: A Multicenter Study.” Annals of neurology (2026). PMID: 42474097 ↗
L3bCited in: Landmark Trials and Key Evidence - [318]
Wang Y, Yan Z, Liu Y et al.. “Localizing the Epileptogenic Zone Using SEEG-Based Excitation-Inhibition Dynamics and Spectral Features in Drug-Resistant Epilepsy: A Multicenter Retrospective Study.” IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society (2026). PMID: 42275352 ↗
L3bCited in: Landmark Trials and Key Evidence - [319]
Philliben R, Willis E, Kim-McManus O et al.. “Responsive Neurostimulation for Treatment of SCN1A-Associated Developmental and Epileptic Encephalopathies.” Pediatric neurology (2026). PMID: 42167045 ↗
L4Cited in: Landmark Trials and Key Evidence - [320]
Dilopoulos I, Nickl-Jockschat T, Grözinger M. “Ictal electroencephalography and heart rate as treatment criteria in electroconvulsive therapy: a systematic review of the literature.” European archives of psychiatry and clinical neuroscience (2026). PMID: 42377484 ↗
L1aCited in: History and Physical Examination - [321]
Karagulle M, Oz N, Karaali K et al.. “Macro-structural brainstem volumetry in generalized epilepsy: assessment of subcortical network involvement.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42702667 ↗
L3bCited in: History and Physical Examination - [322]
Pourmotabbed H, Doss DJ, Sainburg LE et al.. “Autonomic Network Signatures of Interictal Cardiorespiratory Dysfunction in Patients With Temporal Lobe Epilepsy.” Neurology (2026). PMID: 42691468 ↗
L3bCited in: History and Physical Examination - [323]
Ostendorf AP, Brown-Mitchell G, Loddenkemper T et al.. “Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort.” Epilepsia (2026). PMID: 42397688 ↗
L1bCited in: Landmark Trials and Key Evidence - [324]
Uysal U, Landazuri P, Burdette DE et al.. “Responsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months.” Epilepsia (2026). PMID: 42233958 ↗
L1bCited in: Landmark Trials and Key Evidence - [325]
Bamborschke D, Bendella Z, Allen M et al.. “Neuroradiologic Findings in Patients With SCN2A Disease: A Systematic Review and Retrospective Multicenter Cohort Study.” Neurology (2026). PMID: 42758957 ↗
L2aCited in: Landmark Trials and Key Evidence - [326]
Dong Y, Zhu B, Zhang W et al.. “Associations of Acute Seizure Patterns With Functional Outcomes, Mortality, and Remote Seizures After Pediatric Ischemic Stroke.” Journal of the American Heart Association (2026). PMID: 42714418 ↗
L2bCited in: Landmark Trials and Key Evidence - [327]
Duan Y, Huang S, Sha L et al.. “Gestational Changes in Antiseizure Medication Concentrations and the Impact of Polytherapy: A Prospective Multicenter Cohort Study in China.” Neurology (2026). PMID: 42685297 ↗
L2bCited in: Landmark Trials and Key Evidence - [328]
Thorman IB, Sacknovitz A, Goyal A et al.. “Gabapentin and cognitive impairment after traumatic brain injury: A multinational cohort of 49,925 patients.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2026). PMID: 42595621 ↗
L4Cited in: Landmark Trials and Key Evidence - [329]
Li Q, He R, Wang X et al.. “Akkermansia muciniphila enhances washed microbiota transplantation in the treatment of epilepsy.” Chinese medical journal (2026). PMID: 42473187 ↗
L2bCited in: Landmark Trials and Key Evidence - [330]
Tokatly Latzer I, Hong W, Zhang B et al.. “Longitudinal EEG, Seizure, and Developmental Patterns in Children With CDKL5 Deficiency Disorder in the First 2 Years of Life.” Neurology (2026). PMID: 42748393 ↗
L3bCited in: Landmark Trials and Key Evidence - [331]
Maure-Blesa L, Carmona-Iragui M, Barroeta I et al.. “Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study.” Lancet (London, England) (2026). PMID: 42692040 ↗
L3bCited in: Landmark Trials and Key Evidence - [332]
Villaverde S, Pedrero-Tomé R, Raimondi F et al.. “A neonatal prognostic score for infants with congenital cytomegalovirus infection (cCMVnet Score).” European journal of pediatrics (2026). PMID: 42667422 ↗
L3bCited in: Landmark Trials and Key Evidence - [333]
Soler Wenglein J, Heidenreich A, Hilbig R et al.. “Febrile Infection-Related Epilepsy Syndrome: Duration of Therapeutic Coma and Treatment Intensity Correlate With Poorer Functional Outcome.” Pediatric neurology (2026). PMID: 42537571 ↗
L3bCited in: Landmark Trials and Key Evidence - [334]
Koh HP, Chen MSY, Tan S et al.. “Status epilepticus in patients with known epilepsy presenting to the emergency department: Predictors and mortality risk.” The American journal of emergency medicine (2026). PMID: 42335572 ↗
L3bCited in: Landmark Trials and Key Evidence